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ABSTRACT 
 
 
Pharmaceutical industry is one of the major industries causing water pollution. In India, It 
generates about Million litres of waste water processed depending upon the process employed 
and product manufactured. Considering the increased demand for Drugs, the Drug based 
industries in India is expected to grow rapidly and have the waste generation and related 
environmental problems are also assumed increased importance. Poorly treated waste water 
with high levels of pollutants caused by poor design, operation or treatment systems creates 
major environmental problems when discharged to surface water or land. Considering the 
above stated implications an attempt has been made in the present project to evaluate one of 
the WWTP for Drug industry. Samples were collected from six points; Raw effluent [P-1], 
Oil and grease trap [P-2], Equalization tank [P-3], Aeration tank 1 [P-4], Aeration tank 2 [P-5] 
and Secondary clarifier [P-6] to evaluate the performance of WWTP. Parameters analyzed for 
evaluation of performance of WWTP are COD, BOD5 at 20° C, TSS, TDS, oil and grease, 
Chloride and Alkalinity. Parameters like pH and oil & grease were used to access the 
suitability of secondary effluent for reuse in gardening or some other purposes. The COD, 
BOD5 at 20° C and TSS removal efficiency of WWTP were reduced upto very great extent 
hence it is suitable to dispose it off into water bodies. 
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1. INTRODUCTION 
 
1.1   What is Pharmacy? 
Pharmacy revolves around people and medicines with special emphasis on the manufacture of 
medicines, their supply, appropriate use and effects. The ultimate concern of pharmacy is to 
ensure that the patient receives the appropriate medicines and benefits from the proper use of 
these.[1] 
The term “pharmaceutical” covers a wide-ranging class of compounds with substantial 
variability in structures, function, behavior, and activity.[2] Developed to elicit a biological 
effect, they are used in both humans and animals to cure disease, ﬁght infection, and/or reduce 
symptoms.[3] 
Pharmacy is the science and technique of preparing and dispensing drugs. It is a health 
profession that links health sciences with chemical sciences and aims to ensure the safe and 
effective use of pharmaceutical drugs.[4] 
The scope of pharmacy practice includes more traditional roles such as compounding and 
dispensing medications, and it also includes more modern services related to health care, 
including clinical services, reviewing medications for safety and efficacy, and providing drug 
information. Pharmacists, therefore, are the experts on drug therapy and are the primary 
health professionals who optimize use of medication for the benefit of the patients. 
An establishment in which pharmacy (in the first sense) is practiced is called a pharmacy (this 
term is more common in the United States) or a chemist's (which is more common in Great 
Britain). In the United States and Canada, drugs tores commonly sell drugs, as well as 
miscellaneous items such as confectionary, cosmetics, office supplies, and magazines and 
occasionally refreshments and groceries. 
The word pharmacy is derived from its root word pharma which was a term used since the 
15th–17th centuries. However, the original Greek roots from pharmakos imply sorcery or 
even poison. In addition to pharma responsibilities, the pharma offered general medical 
advice and a range of services that are now performed solely by other specialist practitioners, 
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such as surgery and midwifery. The pharma (as it was referred to) often operated through a 
retail shop which, in addition to ingredients for medicines, sold tobacco and patent medicines. 
The pharmas also used many other herbs not listed. The Greek word pharmakeia derives from 
pharmakon, meaning "drug", "medicine" (or "poison").[5] 
In its investigation of herbal and chemical ingredients, the work of the pharma may be 
regarded as a precursor of the modern sciences of chemistry and pharmacology, prior to the 
formulation of the scientific method. 
1.2    Pharmaceutical industry 
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals 
licensed for use as medications. Pharmaceutical companies are allowed to deal in generic or 
brand medications and medical devices. They are subject to a variety of laws and regulations 
regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs.[10] 
1.3   Indian Pharmaceutical industry 
The Pharmaceutical industry in India is the world's third-largest in terms of volume.[6] 
According to Department of Pharmaceuticals of the Indian Ministry of Chemicals and 
Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 
2009 was US$21.04 billion.[7] While the domestic market was worth US$12.26 billion. The 
industry holds a market share of $14 billion in the United States.  
According to India Brand Equity Foundation, the Indian pharmaceutical market is likely to 
grow at a compound annual growth rate (CAGR) of 14-17 per cent in between 2012-16. India 
is now among the top five pharmaceutical emerging markets of the world. 
Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006–07 to 
US$8.7 billion in 2008–09 a combined annual growth rate of 21.25%.[7] According to 
PricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global 
pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.[4] 
The government started to encourage the growth of drug manufacturing by Indian companies 
in the early 1960s, and with the Patents Act in 1970.[5] This patent act removed composition 
EIA of pharmaceutical waste a case study of Lesanto Laboratories 2015 
 
3 | P a g e  
 
patents from food and drugs, and though it kept process patents, these were shortened to a 
period of five to seven years. 
The lack of patent protection made the Indian market undesirable to the multinational 
companies that had dominated the market, and while they streamed out Indian companies 
carved a niche in both the Indian and world markets with their expertise in reverse-
engineering new processes for manufacturing drugs at low costs. Although some of the larger 
companies have taken baby steps towards drug innovation, the industry as a whole has been 
following this business model until the present.[6] 
India's biopharmaceutical industry clocked a 17 percent growth with revenues of Rs. 137 
billion ($3 billion) in the 2009–10 financial year over the previous fiscal. Bio-pharma was the 
biggest contributor generating 60 percent of the industry's growth at Rs. 88.29 billion, 
followed by bio-services at Rs. 26.39 billion and bio-agri at Rs. 19.36 billion.[7] 
In 2013, there were 4,655 pharmaceutical manufacturing plants in all of India, employing 
over 345 thousand workers.[8] 
1.4   Effect of pharmaceutical industries on environment 
Medicines have an important role in the treatment and prevention of disease in both humans 
and animals. But it is because of the very nature of medicines that they may also have 
unintended effects on animals and microorganisms in the environment. Although the side 
effects on human and animal health are usually investigated in thorough safety and toxicology 
studies, the potential environmental impacts of the manufacture and use of medicines are less 
well understood and have only recently become a topic of research interest. Some of the 
effects of various compounds most notably anthelmintics from veterinary medicine and 
antibacterial therapeutics are already known, but there are many other substances that can 
affect organisms in the environment.[11] This is further complicated by the fact that some 
pharmaceuticals can cast effects on bacteria and animals well below the concentrations that 
are usually used in safety and efficacy tests. In addition, breakdown products and the 
combination of different biologically active compounds may have unanticipated effects on the 
environment. Although it may be safe to assume that these substances do not substantially 
harm humans, we have only recently begun to research whether and how they affect a wide 
range of organisms in the environment and what this means for environmental health. 
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...we have only begun to research whether and how they affect a wide range of organisms in 
the environment and what this means for environmental health 
...recent monitoring studies have detected low levels of a wide range of pharmaceuticals ... in 
soils, surface waters and groundwater’s 
The scope of this potential problem is not to be underestimated. More than 10 million women 
in the USA alone use oral contraceptives, which eventually find their way into the 
environment. A wide range of human medicines, including antibiotics, statins or cytotoxins 
used in cancer treatment, are produced and used, some in the range of thousands of tons per 
year. It is hard to obtain information on the amount of human medicines used, but recent data 
from Canada indicates that high-use drugs include acetominophen, acetylsalicylic acid, 
ibuprofen, naproxen and carbamazepine . Large amounts of veterinary medicines, such as 
antibacterials, antifungals and parasiticides from aquaculture and agriculture, may also 
contribute to the stress on the environment, particularly as they often find their way directly 
into soils and surface waters unlike human medicines, which usually go through a water 
treatment plant first. The use of antibacterials in aquaculture in the USA alone is estimated to 
be between 92,500 and 196,400 kg per year (Benbrook, 2002), while estimates for the total 
use of antibacterials in US agriculture range between 8.5 and 11.2 million kg annually.[12] 
These human and veterinary therapeutics are released to the environment by various routes. 
Residues released during the manufacturing process may ultimately enter surface waters. 
After administration, human medicines are absorbed, metabolized and then excreted to the 
sewer system. They usually go through a treatment works before they find their way into 
receiving waters or land by the application of sewage sludge. Antibacterials for the treatment 
of fish or shrimp in aquaculture are directly released to surface waters. Veterinary medicines 
used to treat pasture animals are excreted to soils or surface waters. In intensive livestock 
treatments, these medicines are likely to enter the environment indirectly through the 
application of slurry and manure as fertilizers. Other minor routes of entry include emissions 
to air and through the disposal of unused medicines and containers. 
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Fig.1: Routes of pharmaceuticals entering the environment 
Although pharmaceuticals have been released into the environment for decades, researchers 
have only recently begun to quantify their levels in the environment. Using information from 
different countries and on various usage patterns, several prioritization exercises have 
identified those pharmaceuticals that are most likely to be released into the environment . For 
example, data from the UK on annual usage of veterinary drugs was combined with 
information on administration routes, metabolism and ecotoxicity to identify medicines that 
should be monitored in a national reconnaissance programme performed a similar exercise for 
human medicines using information on annual usage and therapeutic dose along with 
predictive models. Although these studies are generally based on country specific 
information, they still provide an indication of those substances that should be investigated at 
the international level. New analytical techniques, such as liquid chromatography coupled 
with tandem mass spectrometry (LC-MS-MS), have allowed us to develop a better 
understanding of how medicines behave in the environment and to determine concentrations 
in wastewater treatment plants, soils, surface waters and groundwater’s.[13] 
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1.5   Reported subtle effects of pharmaceutical compounds on aquatic and terrestrial 
organisms 
Furthermore, pharmaceutical substances are not the only contaminants in environmental 
systems. Aquatic and terrestrial organisms are exposed to a mixture of medicines and other 
substances, including pesticides, biocides and general industrial chemicals. A recent US 
monitoring study detected the antibacterial agent lincomycin in combination with up to 27 
additional chemicals. The study looked only for selected compounds, so many other synthetic 
substances may also have been present. Interactive effects, such as additivity of substances 
with similar modes of action and synergism, are therefore possible. As current environmental 
risk assessments focus on single substances, it is possible that these assessments are 
underestimating the impacts.[14] 
When we begin to consider these interactions, it is important that we do not just focus on 
toxicological endpoints. It is also possible that the environmental behaviour of a substance 
could change in the presence of other substances. Antibacterials, for example, have been 
shown to affect soil microbes, which have an important role in breaking down pesticides. For 
example, studies indicate that veterinary antibacterials may affect sulphate reduction in soil 
and inhibit the decomposition of dung. If a veterinary antibacterial were to be applied in 
slurry to an agricultural field before the application of a pesticide, it is quite possible that the 
environmental impact of the pesticide could be radically changed.[15] 
As very little is known about the impacts of pharmaceuticals on ecological health and the 
interactions of different compounds, some workers are taking a precautionary approach and 
are developing methods to reduce the releases of these substances to the environment. Various 
approaches have been advocated, including the control of pharmaceuticals at the source, the 
segregation of sources, the treatment of waste products to remove pharmaceutical compounds, 
the introduction of husbandry practices and the improvement of disposal systems for out-of-
date medicines and waste containers.[11] Source controls include labelling, controlled disposal 
and urine separation. Segregating sources of pharmaceuticals, such as hospital wastewater, 
which is likely to be heavily contaminated with pharmaceuticals and antibiotic-resistance 
bacteria, should make it possible to focus treatment resources on the most contaminated 
waters. 
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1.6   Approaches to reduce amounts of pharmaceuticals released to the environment 
Pharmaceuticals can be removed when treated through physical processes, such as sorption or 
volatilization, biological degradation or chemical reactions, for instance, through treatment 
with ozone. The suitability of different options are likely to be highly specific for each 
substance. For example, the antibiotic ciprofloxacin is removed by strong sorption onto 
suspended solids of sewage sludge whereas diclofenac and 17α-ethinylestradiol undergo 
significant biodegradation in aged activated sludge. It is therefore likely that a range of 
measures will be required to reduce emissions. Many of the treatment methods, whilst 
removing the pharmaceuticals, may also produce transformation products that are more 
persistent and mobile than the parent compounds, some of which may also have similar or 
enhanced toxicity. Little work has been performed to assess the environmental impacts of 
these transformation products on the environment.[16] 
It is clear that during the past few years a wealth of data has become available on the levels of 
pharmaceuticals in the environment and on their effects on aquatic and terrestrial organisms. 
There are, however, still many questions that need to be addressed before we can eventually 
determine whether residues in the environment are a threat to human and environmental 
health. First, what are the risks of substances that have yet to be studied? Due to resource 
limitations, only a small proportion of pharmaceuticals in use today have so far been 
investigated, and there is a great need to understand how other substances affect the 
environment. Second, how can we better assess ecotoxicity? Current standard ecotoxicity tests 
are probably inappropriate for assessing the impacts of many pharmaceuticals. The use of 
more subtle endpoints, such as changed behaviour, physiology and biochemistry, seem to 
show some merit. Further work should be performed to identify these subtle effects. It is 
likely that many of the technologies now used by molecular biologists for instance, 
proteomics and genomics techniques or large-scale DNA or protein arrays could greatly help 
with this task. 
Third, what do these ecotoxicity data mean in the real world? Although many subtle effects 
have been shown after exposure to pharmaceuticals at environmentally realistic 
concentrations, we need to establish what these data mean in terms of ecological functioning. 
Fourth, what are the risks of mixtures? Pharmaceuticals are unlikely to appear in the 
environment on their own so the current 'single-substance' approach to risk assessment could 
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be underestimating environmental impacts. This also includes possible indirect effects. Little 
work has been done to determine the uptake of pharmaceuticals into organisms and through 
the food chain. Such studies are crucial to determine the potential indirect effects of 
environmental exposure on ecological and human health. A related question is whether we 
should worry about transformation products. Most work so far has focused on the parent 
compounds; however, we know that transformation products are produced in the environment 
and in treatment processes. It is important that we begin to understand the potential impacts of 
these substances. 
Future work must therefore focus on understanding the biotic and abiotic processes 
underlying the release, environmental fate and effects of pharmaceuticals 
Finally, does environmental exposure result in more antibacterial resistance? A wide range of 
antibacterials has been observed in waters and soils and many of these persist for some time. 
It is possible that such exposure will result in the formation of resistant microbes, which could 
pose a serious threat to human and animal health. 
It will be impossible to design and carry out studies to answer each of these questions for 
every single substance that is in use today. Future work must therefore focus on understanding 
the biotic and abiotic processes underlying the release, environmental fate and effects of 
pharmaceuticals. Such an understanding should ultimately allow the development of new 
modelling approaches. For instance, have proposed a comparative plasma concentration 
model that bridges mammalian and fish species, which could provide useful information on 
the probable impacts of pharmaceuticals on fish.[17] Other modelling approaches, such as 
quantitative structure–activity relationships, could allow us to estimate the environmental 
impacts of pharmaceuticals from their chemical structure. Read-across approaches, where 
data from closely related compounds are used to identify the impacts of an untested 
compound, may also help to improve environmental assessment studies. These improved tools 
should allow us to understand better the impacts of pharmaceuticals on the environment. In 
the meantime, we should strive to refine the ways in which we use, handle and treat medicines 
to minimize their releases to the environment. 
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 1.7   AIM 
The aim of this project is to study the impact of pharmaceutical waste & to reduce its harmful 
effect on environment by using some new treatment methods which are very effective & easy 
to treat. It also includes some systems which replace conventional treatment and combines 
clarification, aeration and filtration into a simple and cost-effective process that reduces 
capital and operating costs & make the whole process environmental friendly. 
 
1.8   OBJECTIVE 
 Determine the nature and quantities of hazardous waste originating from 
pharmaceutical industry.    
 Study the physical characteristics, chemical composition and variations of wastewater 
from chemically synthesised pharmaceutical production. 
 Study the effect of pharmaceutical waste on Environment. 
 Examine the improved control technologies & this could be applied to reduce 
hazardous presented by waste. 
 Study the various methods adopted for treatment of pharmaceutical waste. 
 Manage the pharmaceutical waste in such a way that it will cause minimum bad effect 
to Environment. 
 Determine basic performance of biological treatment in terms of effluent quality & 
sludge property. 
 Apply that waste to the anaerobic filter and determine its treatability.    
 Bring the pollutants in wastewater up to permissible concentration to protect 
groundwater and environment. 
 Study the disposal method with properties of pharmaceutical waste. 
 Investigate possible waste toxicity and how to minimize it. 
 To reduce cost of pharmaceutical waste treatment by studying actual properties of 
waste. 
 Minimization of the sludge generated during the treatment of pharmaceutical waste. 
 Make whole process very near to100% efficient &eco-friendly. 
 
 
  
 
 
 
 
 
Chapter 2 
REVIEW OF LITERATURE 
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2. REVIEW OF LITERATURE 
 
2.1   MANAGING PHARMACEUTICAL WASTE 
While not everyone considers the development of knowledge and systems to properly manage 
pharmaceutical waste to be an inherently glamorous field of study, we can all relate to how 
important it is have our household waste managed. A strike by city environmental services 
personnel or a backed up sewer system suddenly becomes a major priority for our health and 
wellbeing. The disposal of waste pharmaceuticals has been a much more subtle, but no less 
important, issue. For many years, pharmacists have been primarily concerned with ensuring 
that wasted drugs were rendered unrecoverable through sewering or incinerating. The focus 
was on insuring that children did not gain access or that illegal diversion did not occur. Not 
too much has changed, except that hospital incinerators are a thing of the past and more waste 
pharmaceuticals are now being disposed of in biohazardous I sharps containers, in lieu of a 
dedicated pharmaceutical waste stream. Sewering remains a common choice. So why should 
we be concerned about this historically rather simple process? Unfortunately, since 
pharmacists do not routinely receive instruction in environmental regulations, we have been 
largely unaware of a large body of law: the federal Resource Conservation and Recovery Act, 
enforced by the Environmental Protection Agency and authorized states, which regulates the 
disposal of solid waste in the United States. [18] 
EPA and hazardous chemical waste In addition to defining “solid waste,” which includes liq- 
uids and gases, RCRA (pronounced rec-rah) also defines hazardous waste  those chemicals or 
formulations deemed to be so detrimental to the environment that they must be segre- gated 
for special waste management and cannot be sewered or landfilled. A number of drug entities 
and pharmaceutical formulations meet the definition of hazardous waste, including such 
common drugs as epinephrine, nitroglycerin, warfarin, nicotine, and seven common 
chemotherapy agents. Endocrine disruptors As if violating the law weren’t enough to get our 
attention, being a generally law-abiding group of professionals, there are other compelling 
reasons to take a hard look at the final resting place of any drug waste we generate. Growing 
evidence indicates that “endocrine disruptors,” those chemicals that mimic natural hormones, 
trigger an identical response, or block natural hormones  are having a dramatic negative 
impact on critical developmental stages in the fetus and newborn.[18]  
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                          Fig 2: Common pharmaceutical waste streams 
 
 
2.2   How do we generate pharmaceutical waste? 
 
In the past, much of the pharmaceutical waste occurring at a pharmacy was due to expired 
pharmaceuticals. The development of reverse distribution companies has enabled pharmacies 
to ship all outdated drugs as products back through these firms for the purpose of returning 
them to the manufacturer for credit. Any outdated items that do not meet the manufacturers’ 
return policy become waste at the reverse distributor which becomes the waste generator, 
since this is where the decision to discard the item is made. This practice has been supported 
by the EPA through two guidance letters to the industry.[19] The letters make it clear, however, 
that while EPA will consider an outdated drug to remain a product until the decision is made 
to discard it, reverse distribution cannot be used solely as a waste management tool. 
Obviously waste like materials, such as partial vials, compounded IVs, and broken or spilled 
materials, must be considered waste at the pharmacy and managed in compliance with RCRA. 
Other sources of pharmaceutical waste include undispensed compounded products, 
discontinued indated items, unused unit dosed items, unused IVs, and patients’ personal 
medications.[19] 
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2.3   Waste generation status 
 
If an organization generates hazardous waste, it falls into one of three categories, based on the 
amount generated per month: 
1. Conditionally Exempt Small Quantity 
2. Small Quantity 
3. Large Quantity 
Small and large quantity generators8 must notify EPA of their generation activities and 
receive an EPA identification number which remains with the physical site regardless of 
change in ownership or operation. The caveat which boosts pharmacy waste generation into 
large quantity status is the generation of more than 1 Kg. (2.2 lbs) of P-listed waste in a 
calendar month. [20]Which leads to the question, which drugs become hazardous waste when 
discarded? 
 
2.4   Defining hazardous pharmaceutical waste 
 
Applying RCRA to waste pharmaceuticals, we find the following definitions:[21] 
� The P list9 
� The U list10 
� The four characteristics of hazardous waste 
• ignitability 
• toxicity 
• corrosivity 
• reactivity. 
P-listed chemicals are considered “acutely hazardous” by EPA  the worst of the worst. If a 
chemical on the P list is the sole active ingredient of a discarded product, it causes the entire 
product, including the solvent and container, to be contaminated and must be treated as a 
hazardous waste. Pharmaceuticals on the P list include: 
� arsenic trioxide (P012) 
� epinephrine (P042) 
� nicotine (P075) 
� nitroglycerin (P081) 
� physostigmine (P204) 
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� physostigmine salicylate (P188) 
� warfarin over 0.3% (common dosage forms) (P001) 
 
U-listed chemicals include a broader range of pharmaceuticals and again must be the sole 
active ingredient to come under regulation. From the scientific perspective of a pharmacist, 
the sole active ingredient criterion is suspect. For example, the topical anesthetics Fluori-
Methane® and Aerofreeze® both contain two U-listed chemicals, dichlorodifluoromethane 
and trichloromonofluoromethane. Technically, these items would not be regulated as 
hazardous waste when discarded since neither U-listed ingredient is the sole active ingredient. 
Common sense and professional knowledge, however, should lead us to manage these as 
hazardous wastes. This same lack of rationality plagues the regulation in the case of 
chemotherapeutic agents. The P and U lists have not been updated substantially since 1976, 
when only the seven chemotherapy agents in use at the time were U-listed: 
� chlorambucil (U035) 
� cyclophosphamide (U058) 
� daunomycin (U059) 
� melphalan (U150) 
� mitomycin C (U010) 
� streptozotocin (U206) 
� uracil mustard (U237) 
Our professional knowledge of the toxicity of chemotherapeutic agents should encourage us 
to manage all bulk and residue chemotherapy agents as chemical hazardous waste. See Table  
for a complete list of pharmaceuticals that are P and U-listed. 
 
 
2.4.1   Characteristics of hazardous waste 
 
The EPA defines four characteristics of hazardous waste:[22] 
� ignitability (D001) 
� toxicity (D number specific to the chemical) 
� corrosivity (D002) 
� reactivity (D003) 
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Ignitability has a great impact on pharmaceuticals since any aqueous formulation containing 
24% or more alcohol is ignitable under this definition. In addition, a nonaqueous solution 
such as flexible collodion meets the flashpoint definition of less than 140º F. Oxidizers such 
as silver nitrate and potassium permanganate and aerosols with flammable propellants also 
qualify. Toxicity is by far the most difficult characteristic to identify. The good news is that, 
of about 40 chemicals listed by EPA, only ten of them apply to pharmaceuticals and only in 
concentration levels above a certain regulatory limit (See Table 2 Toxicity Characteristic 
Regulatory Limits). The bad news is that the waste generator is responsible for determining if 
their waste meets that criteria and the exit levels are different for each chemical. For example, 
mercury, which is D009, has an exit level of less than .2mg/Liter causing any preparation 
containing a mercury preservative to come under regulation as a hazardous waste. Vaccines 
and topical eye and ear preparations often contain mercury and must therefore be discarded as 
hazardous waste. Corrosivity is much easier to manage, since it involves very acidic (pH < or 
+ to 2) or very basic (pH> or = to 12.5) chemicals. Normally these would only be found in the 
compounding area. The simplest way to manage these chemicals is to review the 
compounding area annually and contract with a hazardous waste broker to properly package 
and manage any discarded items. The final characteristic that of reactivity, is interesting in 
that the only relevant chemical is nitroglycerin. It is also Plisted, making it significant. 
Fortunately, the EPA recently exempted dosage forms of nitroglycerin from federal 
regulation. 16 ,17 Because the Wisconsin Department of Natural Resources has mirroring 
regulations at the state level, an exemption must also be granted by the WDNR before waste 
nitroglycerin dosage forms can be removed from hazardous waste management by Wisconsin 
pharmacies and health care facilities. Even then, if the waste is being transported to a state 
which has not exempted it, nitroglycerin may need to remain a hazardous waste. 
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Table No. 1: P- and U-Listed Pharmaceuticals[23] 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  Hazardous waste 
Name                                       Number 
                                  Hazardous waste 
Name   Number 
Arsenic trioxide                             P012 
Epinephrine                                   P042 
Nicotine                                         P075 
Nitroglycerin1                               P081                             
Physostigmine                               P204 
Physostigmine salicylate               P188 
Warfarin >0.3%                             P001 
Chloral Hydrate (CIV)2                U034                  
Chlorambucil (chemo)                  U035 
Chloroform                                   U044 
Cyclophosphamide (chemo)         U058 
Daunomycin (chemo)                   U059 
Dichlorodifluromethane                U075 
Diethylstilbestrol                           U089 
Formaldehyde                               U122 
 
Hexachlorophene                          U132 
Lindane                                         U129 
Melphalan (chemo)                       U150 
Mercury                                         U151 
Mitomycin C (chemo)                   U010 
Paraldehyde (CIV)                        U182 
Phenacetin                                     U187 
Phenol                                           U188 
Reserpine                                      U200 
Resorcinol                                     U201 
Saccharin                                      U202 
Selenium sulfide                           U205 
Streptozotocin (chemo)                 U206 
Trichloromonofluromethane         U121 
Uracil mustard (chemo)                U237 
Warfarin <0.3%                           U248 
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Table No.2 : D List of Chemicals*[24] 
 
 
Name 
Hazardous 
Waste No. 
                    Regulatory  
                    Level (mg/L) 
Arsenic 
Barium 
 Cadmium 
Chloroform 
Chromium 
M-Cresol 
Lindane 
 Mercury 
Selenium 
Silver 
 
D004 
D005 
D006 
D022 
D007 
D024 
D013 
D009 
D010 
D011 
 
5.0 
100.0 
1.0 
6.0 
5.0 
200.0 
0.4 
0.2 
1.0 
5.0 
 
* D List of Chemicals Present in Pharmaceuticals that Cause a Waste to Exhibit the Toxicity 
Characteristic When Present at or above the Maximum Concentration or Regulatory Level. Note: 
For a complete listing of all 40 chemicals and their regulatory limits, see Section 4, CFR 261.24 
Toxicity Characteristic. Available at: 
http://www.access.gpo.gov/nara/cfr/cfrhtml_00/Title_40/40cfr261_00.html Accessed August, 
2002. 
 
 
2.5   Treatment of Pharmaceutical Waste with Special Emphasis to Treatment Processes  
 The appearance of pharmaceuticals and personal care products (PPCPs) in the natural 
ecosystem poses a great threat for the human beings if not treated. The occurrence of these 
pharmaceutical effluents is generally prevalent in the aquatic environment and this pose a 
serious threat to public health, as we need water for every work, whether it is ground water or 
surface water.[25] This leads to an increasing problem due to the probable environmental risks 
and the supply and transmission of antibacterial resistance amid microorganisms . Various 
types of PPCPs can be found in the effluents from sewage treatment plants, hospitals, 
livestock farms, pharmaceutical manufacturers, dairy industries, slaughterhouses, and 
households.[26] Among these PPCPs, the antibiotic is of major concern, as it is used by both 
animals and human beings. The antibiotics which are transported in the aquatic environment 
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from different sources may either lead to increased antibiotic resistant bacteria or some 
detrimental effects on water quality or both. The frequent use of antibiotics accelerates the 
development of the antibiotic resistant genes in bacteria which causes fatal health risks to 
animals and human beings. The continuous exposure of the bacteria even in minimal 
concentration to antibiotics or active metabolites could lead to the development of resistant 
bacterial strains .Previous studies done by several scientists shows that most of the antibiotic 
compounds displayed direct toxic effects and sometimes detrimental effects in mixture were 
also observed.[27]   
 
2.6 Removal Methods and their Efficiency 
 
 The primary source of antibiotics in the environment is the faeces which consists of 
incomplete metabolized antibiotics by both animals and human beings. Secondary sources 
may include the effluents released from the pharmaceutical manufacturing industries and the 
disposal of such unused or expired antibiotics. Residential facilities such as private 
residences, dormitories, hotels, and residential care facilities and commercial facilities such as 
hospitals are the contributors to the municipal wastewater. Other probable contributors of 
antibiotic are the effluents released from the wastewater treatment plants (WWTPs) to the 
surface and groundwater resources and various industries including pharmaceutical plants and 
surface runoff from the cattle sheds.[28] For the treatment of these deadly antibiotics several 
methods have been employed. In these antibiotics there are a variety of classes present namely 
Macrolide, Quinolone, Sulfonamide, Tetracycline, Trimethoprim, Lincosamide, etc. The 
removal efficiency varies differently for different classes of antibiotics.[29] The different 
removal percentages of the antibiotics are shown in the following table. 
 
In the last couple of decades, the enormous production of antibiotics has aided in recovery of 
human from number of ailments from common cough and cold to cancer, but also has been an 
ever increasing source of pollutants in aquatic as well as terrestrial ecosystems. Even a very 
small quantity has shown severe harmful effects. These compounds are persistent and 
resistant to biodegradation and thus go on accumulating in the environment. Thus a variety of 
removal or degradation processes are employed to solve this problem.  From the above table it 
is quite obvious that all treatment processes have proved to be successful in removing the 
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antibiotic from the aqueous matrices. If we can go for a combination of these treatment 
processes then we would get complete removal.  
 
Table No.3 : Different removal rates for antibiotics. 
 
Sl. 
No 
Methods Percentage 
Removal 
References 
1 Activated sludge in WWTP 60 – 100 % Xiaosong et al., 2010 
78 % Chang et al., (2010) 
92 % Golet et al., (2003) 
2 Anaerobically digested sludge 77 – 87 % Golet et al., (2002); Hong et al., 
(2008) 
95 % Chelliapan et al., (2006) 
3 Photocatalysis + Ozonation 97 % Deniz et al., (2012 
) 
4 Ozonation 4 – 50 % Angela et al., (2013) 
5 Ozonation 90 % Andreozzi et al., (2005) 
6  > 90 % Sánches-Polo et al., 
(2008) 
7 Nanofiltration 85- 95 % Ivan et al., (2011) 
8 Membrane Bioreactors 20 – 70 % 
9 Membrane Bioreactors + 
Reverse Osmosis + 
Nanofiltration + Ozonation 
97 - 99 % 
10 Chlorination >90% Adams et al., (2002) 
11 Photo – Fenton 100% Trovó et al. (2008); Elmolla 
and Chaudhuri (2009 a, b) 
12 Combination of Fenton 
oxidation with two-stage 
reverse osmosis 
99.7% Zhang et al., (2006) 
13 Adsorption on granular 
activated carbon 
95% Putra et al., (2009) 
14 Adsorption on bentonite 88% Putra et al., (2009) 
15 Reverse osmosis + 
Nanofiltration 
> 90 % Kosutic et al., (2007) 
16 Removal using metallic iron 100% Ghauch et al., (2009) 
17 Clarification + Chlorination + 
GAC filtration 
47 %, 92%, 
100% 
Stackelberg et al., (2007) 
18 Coagulation/Flocculation/ 
Sedimentation + Rapid sand 
filtration and Granular 
activated 
30 %, ~ 10%, 
16 % = 56 % 
Vieno et al., (2007) 
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carbon filtration + Ozonation 
19 Adsorption on zeolite coupled 
with ozonation 
80 %, 100 % Ötker and Akmehmet- 
Balcioglu (2005) 
20 Ion exchange ~ 90 % Choi et al., (2007) 
21 Electrochemical oxidation 99.5 % Jara et al., (2007) 
 
 
 
2.7   Physio-chemical treatment options 
 
As seen in oxidation reactionssection, conventional wastewater treatment systems can be 
effective in removing some, but not all pharmaceuticals from wastewater. Therefore, other 
treatment technologies have been explored with the intention of finding suitable polishing 
techniques to further reduce pharmaceuticals concentrations. These technologies include 
membrane separation, chemical removal, activated carbon, chlorination, ultraviolet irradiation 
and other novel approaches.[30] The efficiency of these methods for the treatment of 
pharmaceutical wastewater varies significantly and is described below. 
 
2.7.1   Membrane processes 
 
Several membrane types and applications were evaluated for the removal of APIs at pilot and 
fullscale, including microfiltration, ultra filtration, nanofiltration, reverse osmosis, electro 
dialysis reversal, membrane bioreactors and combinations of membranes in series.[31] 
Microfiltration and ultra filtration are generally not fully effective in removing organic 
contaminants as pore sizes vary from 100-1000 times larger than the micro pollutants which 
can slip through the membranes. The pressure-dr iven membrane processes Nanofiltration 
(NF) and Reverse osmosis (RO) have been the focus of attention of many researchers for the 
treatment of drinking water . However, the studies on the use of RO/NF for pharmaceutical 
removal is limited and most of the studies employed NF and RO membranes for tertiary 
treatment in wastewater recycling plant or for treating saline groundwater. [31]RO in different 
configurations showed efficient removal of thirty-six personal care products and endocrine 
disrupting chemicals including antibiotics, lipid regulators, hormones and oral contraceptives, 
antiepileptics and analgesics. RO membranes removed the majority of compounds 
investigated to levels below the limit of detection. However, pentoxifylline, iodopromide, 
dimethyltoluamide (DEET), meprobamate, phosphanetriyltripropanoic acid (TCEP), 
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gemfibrozil, musk ketone and oxybenzone were detected in the permeate of a variety of the 
configurations.[32] A possible reason for this is short circuiting of the membrane or the failure 
of membrane support media. It has investigated the removal of a range of pharmaceuticals 
including hydrochlorothiazide, ketoprofen, diclofenac, propyphenazone and carbamazepine 
using NF and RO technologies for a fullscale drinking water treatment plant, with high 
rejection percentages (>85 %) for all the pharmaceuticals reported.[31] Pharmaceuticals can be 
rejected on NF and RO membranes by one or a combination of three basic mechanisms: size 
exclusion (sieving, steric effect), charge exclusion (electrical) and physico-chemical 
interactions between solute, solvent and membrane.[32] In laboratory-scale cross-flow tests 
with NF-90 membranes rejections of ketoprofen and diclofenac were reported to be greater 
than 90% .In another study with RO membranes the retention of negatively charged 
diclofenac was 95 % .Some studies reported higher removal efficiencies of polar and charged 
compounds in NF/RO processes due to interactions with membrane surfaces.[33] Though both 
NF and RO treatment shows potential as an efficient method for removing pharmaceuticals 
from the wastewater, the disposal of the sludge which could contain the pollutant in a more 
concentrated form remains. 
 
2.7.2   Activated carbon (AC) 
 
AC is a recognised conventional technology for the removal of both natural and synthetic 
organic contaminants . It is most commonly applied as a powdered feed or in granular form in 
packed bed filters. Granular activated carbon (GAC) can be used as a replacement for 
anthracite media in conventional filters, providing both adsorptionand filtration. It can be 
applied following conventional AS treatment as an adsorption bed. However, carbon 
regeneration and disposal are environmental considerations.[34] In general, sorption is 
described using Freundlich isotherms, with sorption behaviour quantified as the specific 
sorption coefficient, KD (L/mg) . This coefficient is the ratio of equilibrium concentrations of 
a dissolved compound in a system containing a sorbent (AC or sludge or solids) and an 
aqueous phase and expressed as: 
 
kD =
Csads (eq)
Caw
adc (eq)
 
 
EIA of pharmaceutical waste a case study of Lesanto Laboratories  2015 
 
21 | P a g e  
 
Where Csads (eq) is the amount of the compoundsorbed on the sorbent at sorption 
equilibrium (mg/g),and Caw
adc (eq)is the concentration of the compoundin the aqueous phase at 
sorption equilibrium (mg/L).Sorption is negligible for substances with log KD values less 
than 2, but is large when the log KD valueis greater than 4 (Clara et al., 2005). The reported 
LogKD values of estrogens like Estrone, 17β-Estradiol and17 α-Ethinylestradiol ranged from 
2.2 to 2.8 and 2.0 to 2.84 ,respectively. Since these log KD values are between 2and 4, 
sorption can be suitable as a removalmechanism. Dutta et al. (1997) studied the adsorptionand 
desorption of 6-aminopenicillanic acid (6-APA) in aqueous solution using activated 
carbon.[35] They found that the adsorption process was highly reversible, the extent of 
reversibly adsorbed 6-APA was around 93 %. Snyder et al. (2007) found that both powdered 
activated carbon (PAC) (5mg/L) and GAC removed greater than 90 % of estrogens (100–200 
ng/L initial concentrations). However, dissolved organic compounds, surfactants and humic 
acids compete with binding sites and can block pores within the AC structure. PAC, which 
was used at pilot scale, achieved greater than 90% removal for 19 of 26 APIs tested including 
trimethoprim, carbamezapine and acetaminophen. Poor results were seen where regular 
regeneration was not provided. The filtration step prior to the treatment of micro pollutants by 
PAC is important.[36] The general difficulty with PAC treatment lies in separating the carbon 
from the water.  
 
2.7.3   Chlorination 
 
Chlorination has been shown to be effective for the removal of pharmaceuticals including 
17α- ethinylestradiol and 17 β-estradiol  and sulfonamides (Qiang et al., 2006). Chlorine 
dioxide is also effective for the removal of sulfamethoxazole, roxithromycin, 17α-
ethinylestradiol and diclofenac.[37] Chlorination and ozonation when compared for the 
removal of bisphenol A, 17β- estradiol, and 17α-ethinylestradiol and byproduct estrogenicity 
from distilled water showed comparable results with ozonation resulting in 75-99 % 
removal.Residual chlorine and ozone was found to be low with > 99 % loss of the parent  
compound. Lee and Von Gunten (2009) achieved 90 % conversion of estrogen, 17α-
Ethinylestradiol with chlorine and increased the rate of 17β-Ethinylestradiol transformation 
by a factor of 3 with the addition of 0.25 mM Br-. The accelerating effect of Br- diminishes in 
the presence of dissolved organic matter as it consumes bromine faster than 
estrogens.[38]Acetaminophen, diclofenac, sulfamethoxazole and fluoroquinlone all become 
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oxidised during chlorination. By-products of acetaminophen include the toxic byproducts N-
acetyl-p-benzoquinine imine and 1,4 benzoquinone. Both metoprolol and sulfamethoxazole 
form carcinogens such as chloramines as one of their oxidation products and this may be due 
to the fact that ammonia chlorination was about one thousand times faster than phenol 
chlorination . 
 
2.7.4   Ozonation 
 
Ozone has been applied to the treatment of waters primarily due to its strong disinfection and 
sterilization properties . Its application for the treatment of waters containing pharmaceutical 
residues is now a broad area of research .The main mode of action in the ozonation process is 
the formation of OH- radicals due to ozone decay in the water, but there are also ozone 
molecules present for chemical attack. This increases the oxidation capacity .[39] Ozonation 
has been implemented as the principle treatment method or to enhance the biodegradability 
and efficiency of subsequent treatment. Ozone production is an energy intensive process, 
making it costly to implement. An ozone treatment system may increase the energy demand 
over a conventional wastewater treatment plant by 40-50 % . The use of ozone as a means of 
breaking down pharmaceuticals in water has been the subject of numerous studies over the 
last ten years including . A significant contribution to this work has been in the area of 
antibiotic removal ,where removal rates >90 % have been reported. However, the reported 
removal rate for lipid regulators is less at about 50 % and about 60-80 % for β-blockers and 
below 50 % for some Antiphlogistics . Although the degree of removal and mineralization of 
pharmaceuticals in water or synthetic industrial effluent has been reported, little or no 
literature exists on the ozonation of pharmaceuticals in actual pharmaceutical wastewater . 
Furthermore details of process optimisation and kinetics for the elimination of 
pharmaceuticals using ozone are limited. Also, disagreement exists for the ozone dose 
necessary for pharmaceutical removal.[40]  
 
2.7.5   Perozonation 
 
Perozonation, a combination of hydrogen peroxide and ozone, has been successfully used to 
degrade penicillin formulation effluent. The conjugate base of H2O2 at low concentrations 
increases the rate of decomposition of O3 into hydroxyl radicals.[39,41] 30 % removal of COD 
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in penicillin formulation effluent was accomplished using ozonation alone . Removal 
efficiency was enhanced through the addition of H2O2,to a maximum of 76 % in the presence 
of 2mM of H2O2. However, it was found that a certain fraction of the resulting COD was non 
biodegradable in the subsequent biotreatment. This inert fraction of the waste remained in the 
effluent.[41] Only overall COD loading was monitored and not actual penicillin levels or 
breakdown compounds . Thus, the true treatment efficiency of the method in terms of the 
penicillin removal was unclear. Cogar has investigated the pretreatment of synthetic penicillin 
formulation effluent containing procain penicillin G (PPG) with the O3/H2O2process (applied 
ozone dose = 1440 mg/h treatment time = 60 min; pH 7; H2O2 = 10 mM). The effect of 
chemical pretreatment was assessed on the basis of acute toxicity and biodegradability with 
activated sludge using water flea Daphnia magna toxicity.[40,41] The pretreatment resulted in 
more than 70 % COD removal and a 50 % decrease in the acute toxicity towards Daphnia 
magna.Other studies involving penicillin showed COD and aromaticity results increased from 
69 % and 29 % for ozone alone to 95 % and 90 % in the presence of 20mM hydrogen 
peroxide. The presence of UV increased the COD removal in penicillin formulation 
wastewater to almost 100%.[41] For synthetic formulation effluents containing the antibiotics 
like ceftriaxone and enrofloxacin, only slight increases in efficiency were noted following the 
addition of hydrogen peroxide. Combined UV, O3 and H2O2 treatment was applied to a 
municipal wastewater treatment plant effluent containing seventeen pharmaceuticals 
including antibiotics, β-blockers, antiepileptics, antiphlogistics and lipid lowering agents at a 
German Municipal WWTP. Removal of all target analytes below detection limits was noted 
following 18 min contact time at an ozone dose of 10-15 mg /L, with the exception of the 
iodinated X-ray contrast media, diatrizoate, iopamidol, iopromide and iomeprol which 
showed removal efficiencies of not higher than 14 %. Diatrizoate was removed by only 25 % 
following 10 mg/L O3. The addition of H2O2 only slightly increased removal efficiency. The 
removal rates for a variety of pharmaceuticals using hydrogen peroxide showefficiencies 
ranging from 40 % for Acetominophen to >95 % removal for some hormones when combined 
with UV.[42] 
 
2.7.6   Fenton reactions 
 
Fenton chemistry involves reactions of hydrogen peroxide in the presence of iron to generate 
hydroxyl radicals.[44] Ultraviolet light enhances this generation by the photo reduction of Fe 
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(III) to Fe (II). Since iron is abundant and non-toxic, Fenton reactions are a viable option for 
wastewater treatment. Photo- Fenton reactions have been used for the degradation of 
diclofenac .Complete mineralisation of diclofenac and its intermediates via photo-Fenton 
reactions in a concentric photo reactor took approximately 50 min. Compound parabolic 
collectors have also been used to mineralise diclofenac in approximately 60 min. Another 
advantage of Fenton reactions is that mineralisation is possible in sunlight avoiding the use of 
UV light. Fenton (Fe2+/ H2O2) and Fenton-like (Fe3+/H2O2) reactions were compared for 
both dark and photo-assisted reactions. Penicillin was completely removed after 40 min of 
advanced oxidation with Fe2+/H2O2 at pH 3.[44] Higher COD and Total organic carbon 
(TOC) removals were obtained with dark Fe2+/ H2O2 at pH 3 compared with dark Fenton-
like Fe3+/H2O2.[42] Photo-assisted reactions using UV-C provided only slightly higher 
removal efficiencies. TOC removal was higher with photo-Fenton reaction and COD removal 
was slightly higher with photo-Fenton-like reactions. Since Fenton reactions operate at room 
temperature normal pressure and without the highly complicated apparatus, there should be a 
smooth transition from laboratory scale to large scale. On the other hand, the strong 
dependence on the aqueous solution pH (optimum pH 2-4 for the production of OH.[44,43] 
Radicals and on the concentrations of hydrogen peroxide and ferric / ferrous ions and the 
disposal of the iron sludge are factors which need to be taken into consideration. One 
possibility is the partial use of Fenton reactions to produce a non-toxic and biodegradable 
intermediate which could then be treated in an inexpensive biological step to achieve 
complete mineralization.[43] 
 
2.7.7   Direct photolysis 
 
Direct photolysis occurs due to the breakdown of a compound by the absorption of light. 
Indirect photolysis is caused when photo sensitisers, such as nitrate and dissolved organic 
matter, absorb light and generate reactive oxygenated radicals that subsequently degrade other 
compounds. Many pharmaceuticals are readily susceptible to photolytic transformation.[43] 
APIs that do not absorb light above 290 nm are more resistant to direct photolysis with natural 
light. Lamps employed in the removal of micropollutants focus mainly on low and medium 
pressure mercury lamps. Low pressure mercury lamps characteristically generate light at 254 
nm while medium pressure lamps emit their energy at multiple wavelengths. Using a 110W, 
254 nm UV lamp at 313K and 0.5 g/L, a 70 % conversion of 0.25 L of 2-chloropyridine 
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(typically found in effluent of pharmaceutical processing) was achieved in 20 min. 
Mefenamic acid was observed to undergo direct photolysis with a half-life of 33 h under 
direct noon sunlight in mid-October at 45° latitude. Carbamazepine and clofibric acid have 
photodegradation half-life times of 100 d in winter at 50°N. Conversely sulfamethoxazole, 
diclofenac, ofloxacin and propranolol undergo faster degradation with half-lives of 2.4, 5.0, 
10.6 and 16.8 days, respectively. In a different set of experiments, clofibric acid, diclofenac, 
fenoprofen, isopropylantipyrine, ketoprofen, phenytoin and triclosan were removed in a 
laboratory situation (>96 %) by ultraviolet photolysis alone. A fundamental parameter that 
determines the rate of degradation for photolysis is the decadic molar absorption coefficient. 
The decadic molar extinction coefficient is a measure of the capacity of a compound to absorb 
light. Ibuprofen, diphenhydramine, phenazone, and phenytoin have decadic molar extinction 
coefficients of 256/M/cm, 388/ M/cm, 8906/M/cm and phenytoin 1260/M/cm, respectively. 
As indicated by the decadic molar extinction coefficients, 27.4 % removal of 5 μm initial 
concentration of ibuprofen, 26.34 % of diphenhydramine, 95.78 % and 87.75 % degradation 
for phenazone and phenytoin, respectively, was observed. The experiment was carried out 
using a 11W low pressure lamp producing monochromatic UV light at 254 nm in a 500 mL 
quartz reactor. The antibiotic metronidazole achieved only 6 % removal with a low-pressure 
and 12 % with a medium pressure mercury lamp after 5 min exposure. Metronidazole has a 
crucial absorption centered at about 310 nm, which can be readily excited by a medium 
pressure lamp. In contrast, low pressure lamps only emit light at 254 nm and as a result, the 
important absorption at 310 nm is missed. The adsorption-lamp emission mismatch 
consequently explains the low removal with UVC light. As such,direct photolysis on its own 
is not an effective forremoving pharmaceuticals from wastewater. Alternatively, photolysis 
coupled with Fe (III) and H2O2or TiO2 can remove over 98 % of pharmaceuticals including 
estrogens.[45] 
 
2.7.8   TiO2 photocatalysis 
 
Photocatalysis is the acceleration of a photochemical transformation by the action of a catalyst 
such as TiO2or Fenton’s reagent. Most photo catalysts are semiconductor metal oxides which 
characteristically possess a narrow band gap. Radicals formed degrade impurities in the water 
relatively unselectively, reacting with impurities in the waste water as well as the target 
pharmaceuticals. Since the degradation of chlorobipenyls and biphenyls from aqueous media 
EIA of pharmaceutical waste a case study of Lesanto Laboratories  2015 
 
26 | P a g e  
 
using TiO2photocatalysis was first reported the number of publications on the removal of 
micropollutants from aqueous media using TiO2 has grown considerably. Titania is the most 
widely investigated of the heterogeneous photocatalyst dueto its cost effectiveness, iner t 
nature and photostability.[46] Investigations into the removal of the pharmaceuticals using 
TiO2, include but are not limited to work on antibiotics, lipid regulators, x-ray contrast media, 
antiepileptics and antiphlogistics. Removal rates have been reported at 98 % for antibiotics 
when used in combination with UV. However, removal rates for carbamazepine are under10 
%. TiO2 is available at arelatively modest price and would be recyclable in anindustrial 
application when fixed on films or beads, reducing the quantities of TiO2 required . 
Furthermore, solar studies have proved effective for a wide range of pharmaceuticals 
replacing theexpense of generating UV light. There are difficulties in implementation on a 
commercial scale due to the number of operating parameters e.g. type and geometry of 
reactor, the photocatalyst, optimum energy use and wavelength of radiation. Moreover, it is 
difficult to assess the true success of the photocatalytic process in the absence of identified 
intermediate compounds and end products.[47] 
 
2.8   Photocatalytic reactors and reaction kinetics 
 
In the development of photocatalytic reactors, many factors need to be considered including 
mass transfer, reaction kinetics, mixer, catalyst installation and catalyst illumination. Based on 
the arrangement of the light source, reactor configurations can be categorised as:[48] 
1) immersion type where lamps are inserted into the reactor, and 2) external type where lamps 
are put outside the reactor. One of the major impediments to the commercialisation of 
photocatalytic water treatment is the high cost of generating artificial radiation. Therefore, 
solar photocatalytic reactors have received considerable interest. To ensure efficient 
conversion of the incident solar radiation to charge carriers, the design of the solar reactor is 
extremely important. There are four frequently used reactor configurations: Parabolic trough 
reactor (PTR), Thin film fixed bed reactor (TFFBR), Compound parabolic collector (CPC) 
and Double skin sheet reactor (DSSR) . PTRs concentrate sunlight into a focal line using 
parabolic mirrors. A TFFBR consists of a sloping plate coated with the photocatalyst and 
rinsed with the polluted water in a very thin film.[49] The DSSR is a flat and transparent 
structured PLEXIGLAS®box. The polluted water and the photocatalyst can be pumped 
through channels in the box. A CPC is a combination of parabolic concentrators and flat static 
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systems. Reactors can also be classified into concentrating and non-concentrating. These two 
types of reactors are compared in Table below. CPCs are low concentration collectors which 
are a good option for solar photocatalysis since they combine the better features of 
concentrating and non-concentrating collectors and none of the disadvantages. The 
photoreactor is tubular so that water can be pumped easily. CPCs use direct and diffuse solar 
radiation efficiently without solar tracking. The water does not heat up and there is no 
evaporation of volatile compounds . 
                                Table No.4 : Comparison of reactor types. 
Example Concentrating 
PTR 
Non-concentrating 
TFFBR, DSSR and CPC 
Advantages Turbulent flow conditions which 
favour mass transfer and avoid 
catalyst sedimentation problems 
 
Two axis sun tracking system  
Nearly closed reactor-no 
vaporisation of volatile 
Contaminants 
 
Smaller reactor tube area which is 
able to support higher pressures and 
a large amount of area per unit 
volume 
 
Total global irradiation is usable 
 
High optical efficiency 
 
Low manufacturing costs due to its 
simple construction 
 
No additional H2O2 necessary since 
there is effective transfer of air into 
the water film. 
 
High quantum efficiency 
 
No heating needed 
Disadvantages Only direct irradiation can be used 
 
 Low optical efficiency  
 
Since sun-tracking is needed there 
are high investment costs 
 
The TiO2 needs to be separated 
from the purified water  
The volatile reactants can vaporize 
 
The catalyst is not protected from 
pollution 
 
A large catalyst area is needed when 
purifying large volumes of 
wastewater 
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Water over-heating can lead to 
leaks and corrosion Additional 
H2O2 may be needed 
There is low mass transfer due to the 
laminar flow conditions 
Requires significantly more 
photoreactor area 
 
 
 
 
 
2.9   Electrochemical treatment options 
 
Electrochemistry is a relatively new method for the treatment of wastewater. The treatment of 
acetaminophen using anodic oxidation with a Borondoped diamond (BDD) electrode has been 
successful during small scale investigations. This process allows complete mineralisation of 
the acetaminophen due to the generation of large concentrations of hydroxyl radicals by the 
electrode. The BDD electrode was efficient even at low concentrations. BDD has high 
thermal conductivity, wide band gap, high and hole mobilities, highbreakdown electric fields, 
hardness, optical transparency and chemical inertness.[50] 
Ultrasonic irradiation has been considered as a means of removing estrogenic compounds 
from contaminated water. Hormones, for example, estradiol, estrone and ethinylestradiol, 
were examined in single component batch and flow through reactors using 0.6, 2 and 4 kW 
ultrasound sources. Results showed 80- 90 % reduction in the hormones within a 40-60 min 
period . Further investigations in this area would be useful to determine the toxicity of 
breakdown products and to examine the feasibility of larger scale applications of the 
technology.[51] Diamond anodes may produce OH. radicals with high current efficiency. This 
is dependent on the mass transport of organic compounds to the anode not being a limiting 
factor. 
 
2.10   Assessing the exposure risk and impacts of pharmaceuticals in the environment on 
individuals and ecosystems[52] 
 
The use of human and veterinary pharmaceuticals is increasing. Over the past decade, there 
has been a proliferation of research into potential environmental impacts of pharmaceuticals 
in the environment. A Royal Society-supported seminar brought together experts from diverse 
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scientific fields to discuss the risks posed by pharmaceuticals to wildlife. Recent analytical 
advances have revealed that pharmaceuticals are entering habitats via water, sewage, manure 
and animal carcasses, and dispersing through food chains. Pharmaceuticals are designed to 
alter physiology at low doses and so can be particularly potent contaminants. The near 
extinction of Asian vultures following exposure to diclofenac is the key example where 
exposure to a pharmaceutical caused a population-level impact on non-target wildlife. 
However, more subtle changes to behavior and physiology are rarely studied and poorly 
understood. Grand challenges for the future include developing more realistic exposure 
assessments for wildlife, assessing the impacts of mixtures of pharmaceuticals in combination 
with other environmental stressors and estimating the risks from pharmaceutical 
manufacturing and usage in developing countries. We concluded that an integration of diverse 
approaches is required to predict ‘unexpected’ risks; specifically, ecologically relevant, often 
long-termand non-lethal, consequences of pharmaceuticals in the environment for wildlife and 
ecosystems. 
 
The continued expansion of the human population is leading to escalating demand for 
resources, including human and veterinary pharmaceuticals. Pressures are exerted by 
increasingly intensive agriculture and exacerbated by rising human longevity and obesity, 
leading to more health problems. With this comes a proliferation in the quantity and diversity 
of pharmaceuticals consumed and subsequently excreted. While the health benefits of 
medicationare fundamentally important, it is only in the past decade that the potential 
environmental impacts of pharmaceuticals have begun to be considered in detail . At a recent 
Royal Society funded Research Fellow International Scientific Seminar, experts from diverse 
research fields discussed the risks to wildlife posed by pharmaceuticals in the environment. 
Our conclusions have policy relevance to the ongoing debate in the EU over the prospect of 
environmental quality standards for specific pharmaceuticals. Pharmaceuticals are a 
potentially potent group of chemical contaminants, because they redesigned to have biological 
effects at low concentrations. Given evolutionary conservation across vertebrate taxa, both 
human and veterinary pharmaceuticals may be predicted to act on many non-target species . It 
is also now emerging that pharmaceuticals and their biotransformation products are present in 
a range of habitats, some can bioaccumulation and may have significant, but largely 
unstudied, consequences for individuals, populations and ecosystems . 
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2.10.1   17a-ethinyloestradiol and non-steroidal anti-inflammatory drugs: lessons 
learned and wider implications for wildlife 
 
The two clearest cases of pharmaceuticals affecting wildlife to date involve 17b-oestradiol 
(E2) and the synthetic oestrogen 17a-ethinyloestradiol (EE2), and the non-steroidal anti-
inflammatory drug (NSAID), diclofenac.[53,54] There is now convincing evidence of the 
feminization of male fish downstream of sewage treatment works (STWs) discharging 
complex effluent, which includes E2 and EE2 from the contraceptive pill and hormone-
replacement therapies.[53] While deleterious effects have been found on reproductive traits of 
individuals, Susan Jobling (Brunel University) showed that individual male reproductive 
success in breeding groups declines with increased feminization, but intersex fish can still 
breed. Jobling’s group has estimated modest increases in oestrogen equivalents in the UK’s 
waterways over the time period to 2050. Thus, it seems pertinent to ascertain public opinion 
regarding intersex fish in European rivers and willingness to pay for water treatments that 
remove harmful levels of pharmaceuticals and other micro-pollutants from effluents. Three 
Asian vulture species are now critically endangered because of acute toxicity following 
consumption of the carcases of diclofenac-treated livestock. Richard Cuthbert’s (RSPB) work 
has been instrumental in banning the sale of diclofenac for veterinary use and promoting the 
sale of a vulture-safe alternative.[54] Consequently, there is an indication that endangered 
vulture populations are starting to recover, although numbers remain very low (less than 1% 
of previous levels) across South Asia. However, residues of diclofenac and other potentially 
toxic NSAIDs are still being detected in dead vultures.  
 
2.10.2   Exposure pathways for wildlife 
 
Recent improvements in analytical technologies have enabled the detection and quantification 
of pharmaceuticals in environmental matrices, including surface waters and soil. However, 
efforts need to be targeted and measured concentrations presented within a risk-based context. 
Exposure risk can be estimated from prescription and sales figures, then refined based on the 
excretion of un-metabolized ‘parent compounds’ or bioactive metabolites, persistence in the 
environment and potential to bioaccumulate in food chains.[55] Such an approach has been 
used by Chris Metcalfe (Trent University) to predict environmental concentrations of 
antidepressants. Long-term monitoring of pharmaceuticals in rivers and lakes confirmed the 
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presence of antidepressants and other pharmaceuticals in plumes around STW outflows. Wild 
fish caged within these plumes exhibited significant changes in a range of biomarkers, but 
consequences for individual fitness and population persistence are unknown. Monitoring 
exposure to pharmaceuticals in terrestrial ecosystems is less well developed than in 
freshwater, but transferable techniques have been used to assess exposure risk to plant 
protection products on farmland.[56] Via radio-tracking, Helen Thompson (FERA) has mapped 
how wild birds and mammals disperse around contaminated resources at the landscape scale, 
which could also be used to record the movements of terrestrial vertebrates on STWs or 
sewage sludge fertilized fields, for example. At the national level, Richard Shore (CEH) 
suggested that current wildlife monitoring schemes, for example, the Predatory Bird 
Monitoring Scheme (http:// pbms.ceh.ac.uk/), could be adapted to include surveillance for 
pharmaceutical exposure in addition to other contaminants . Temporal and spatial trends in 
pharmaceutical exposure could therefore potentially be traced. As with terrestrial habitats, 
there is a lack of data on pharmaceutical exposures for the marine environment, highlighted 
by Sally Gaw (University of Canterbury), despite it being a major receptor for wastewater due 
to increasing human habitation of coastal areas and more intensive use of pharmaceuticals in 
aquaculture.[56] 
 
2.10.3   Uptake and fate of pharmaceuticals in food webs 
 
In contaminated environments, uptake of pharmaceuticals by invertebrates was shown by 
Alistair Boxall (University of York) to vary depending on the chemistry of the environmental 
matrix and species’ mode of feeding, thus effects can be difficult to predict . Similarly, in 
terrestrial vertebrates, understanding consequences of group versus solitary feeding, or 
responses to novel food types, is important when designing captive experiments to calculate a 
realistic uptake rate . Extending his work on the uptake and fate of NSAIDs in Asian vultures 
, Mark Taggart (University of the Highlands and Islands) is also analyzing vulture and 
livestock samples with the aim of assessing the true risk of veterinary antibiotics to 
scavenging birds in Spain, a stronghold for vultures in Europe.[57] Understanding the ecology 
of susceptible, exposed animals is vital. 
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2.10.4   Effects of pharmaceuticals on wildlife[58] 
 
The paucity of studies on the effects of pharmaceuticals on non-model, particularly terrestrial, 
species was further highlighted by Judit Smits (University of Calgary). Essentially, we now 
need further development of non-lethal assays or biomarkers of subclinical toxicity following 
exposure to contaminants, for example, biotransformation enzymes and hormones . Key 
features of an ideal sentinel for pharmaceutical risk in the wild include natural risk of 
exposure, toleration of human disturbance and relevance to the food web of interest. One such 
species is the European starling Sturnus vulgaris, which commonly feeds on pharmaceutical 
contaminated invertebrates living on STWs. The species is robust to capture and captivity and 
forages on invertebrates, a potentially important but unstudied exposure route. Kathryn 
Arnold (University of York) found that long-term exposure to an environmentally relevant 
dosage of fluoxetine (Prozac), a commonly used antidepressant, altered physiology, behavior 
and mass balance in starlings. While behaviours are non-lethal and ecologically relevant 
endpoints to measure in such studies, they can be challenging to analyse and interpret because 
of the high degree of individual variability . Standardized laboratory tests and endpoints are 
required in order to ensure the reliability and repeatability of ecotoxicological studies. 
Exposure conditions and test organisms need careful consideration, as, for example, there may 
be significant inter- and intraspecies variation in sensitivity, requiring the use of additional 
safety factors. Although many studies claim to use outbred strains, which areconsidered more 
representative of wild populations, these claims are rarely supported by pedigree or genetic 
evaluation. Ross Brown (AstraZeneca and University of Exeter) has shown that inbred family 
lines of zebrafish can differ significantly in their physiological and developmental responses 
to pharmaceuticals, compared with outbred wild-type family lines. 
 
 
2.11   WASTEWATER MANAGEMENT 
 
Water consumption and scope of recycling of wastewater 
Consumption of process water is less than consumption of water for utility (boiler/cooling 
water bleeding) 
Utility discharge is relatively cleaner, with renovation it can be reused. 
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Fig No.3:  ALTERNATIVES FOR RECYCLING, RECOVERY, RENOVATION AND 
REUSE OF INDUSTRIAL WASTEWATER [59] 
 
 
Fig No. 4: PROPOSED SCHEMATIC FLOW DIAGRAM FOR THE TREATMENT 
OF  EFFLUENT FROM FORMULATION UNITS 
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Fig No.5:  PROPOSED SCHEMATIC FLOW DIAGRAM FOR THE TREATMENT 
OF EFFLUENT FROM BULK DRUG UNITS [59] 
 
 
 
Fig No.6: DECISION TREE FOR APPROPRIATE TREATMENT OF 
WASTEWATER 
 
EIA of pharmaceutical waste a case study of Lesanto Laboratories  2015 
 
35 | P a g e  
 
 
Fig No. 7: STREAM WISE BPT IN BULK DRUG INDUSTRIES[59] 
 
 
 
Fig No.8: INTEGRATED TREATMENT SCHEME THROUGH COMBINED 
EFFLUENT TREATMENT PLANT IN A CLUSTER OF INDUSTRY 
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2.12   AIR POLLUTANTS 
Conventional air pollutants 
• SPM, SO2 & NOx from utilities like boiler/DG sets and from unit operation. 
Hazardous air pollutants (HAPs) and odorous compounds 
• Solvents from solvent extraction and solvent in reaction media. HAPs are benzene, carbon 
tetrachloride, 1-4 dioxane, methanol, toluene, methyl chloride etc. These are hazardous and 
confirm carcinogenic. 
• The odorous compounds are mercaptans and hydrogen sulphide. 
 
 
 
 
 
                                           Table No.5: Table for bulk drug density 
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                                        Table No.6:Air pollution control system 
 
2.13   SOLID WASTE MANAGEMENT IN BULKDRUG INDUSTRY 
 
Solid waste generated in bulk-drug industry can be classified into three categories: 
a) Engineering solid waste like metals, scrap, glass, plastic, drums/carboys is generally sold 
out for their further reprocessing. 
b) ETP sludge 
• From the formulation unit & fermentation unit, 
• Mycelium cake coming out from the fermenter, 
• Solid waste such as residue and rejected batch material. 
c) Toxic and hazardous waste such as residue, reject batch material etc. from the process. 
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2.14   ENVIRONMENTAL MANAGEMENT AND SELF EVALUATION 
 
• Adoption of ISO standards like ISO 14000, 9000, regular auditing and development of road 
map are components of self-assessment. 
• The environmental management system may comprise in-plant control, right choice of 
technology, appropriate engineering practices along with end-on-pipe treatment. 
• The sequential chain needs an integration of production manager, project manager, R & D, 
quality control and environmental manager 
 
2.15   CHARTER ON CORPORATE RESPONSIBILITY FOR ENVIRONMENTAL 
PROTECTION FOR PHARMACEUTICAL SECTOR [59] 
 
2.15.1 Segregation of waste streams 
Waste streams should be segregated into high COD waste, toxic waste, low COD waste, 
inorganic waste etc, for the purpose of providing appropriate treatment. Implementation by 
December 31, 2003 and action plan to be submitted to SPCB by June 30, 2003. 
 
2.15.2Detoxification and treatment of high COD waste streams 
High COD streams should be detoxified and treated in ETP or thermally destroyed in 
incinerator- Implementation by March 2004 and action plan to be submitted to SPCB by June 
2003. 
 
2.15.3   Management of solid waste 
Proper facilities should be provided for handling and storage of hazardous waste. For final 
disposal of hazardous waste, recycling and reuse should be given priority, either within the 
premises or outside with proper manifest system. In case of incinerable waste, properly 
designed incinerator should be installed within the premises or disposed of outside in a 
common facility. The non-incinerable hazardous waste should be disposed of in properly 
designed secure-landfill either within the industry’s premises or in a common facility-
Implementation by December 31, 2003 and action plan to be submitted to SPCB by June 
2003. 
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2.15.4   Minimum scale of production to afford cost of pollution control 
For new industries which are not connected with CETP & TSDF and which do not have the 
economics to install treatment facilities may not be considered for granting consent to 
establishment. Industry association shall submit proposal to SPCB/CPCB-Implementation by 
December 31, 2003 and action plan to be submitted to SPCB by June 30, 2003. 
 
2.15.5   Long term strategies for reduction in waste 
Consent for establishment and consent for operation under the Water Act will be based on 
pollution load and concentration of pollutants. Each industry will submit pollution load, 
concentration of final discharge along with water balance to SPCB/CPCB for formulation of 
strategy-action plan to be submitted to SPCB by June 31, 2003. 
 
2.15.6   Control of air pollution 
Industry will take up on priority, the control of hazardous air pollutants (such as benzene, 
carbon tetrachloride, 1-4 dioxane, methanol, toluene, methyl chloride etc.) and odorous 
compounds (mercaptans & hydrogen sulphide) - Implementation by December 2004 and 
action plan to be submitted to SPCB by June 2003. 
 
2.15.7   Self-regulation by Industry through regular monitoring and environmental 
auditing 
Industries on their own will carry out monitoring of environmental parameters, audit it at 
regular interval and submit the same to SPCB-Implementation by June 2003. Comment on 
BDMA-There shall be a policy for accreditating the auditors and the policy guidelines may be 
issued by MoEF. 
 
2.15.8   Organizational restructuring and accreditation of Environmental Manager of 
Industry 
a) Environment management cell will be created for each industry reporting to CEO directly 
Implementation by June 2003. 
b) There should be a certification system for the environmental managers at individual level 
and common facility level. BDMA may evolve the programme along with SPCB/CPCB-
Implementation by March 31, 2004 and action plan to be submitted to SPCB by July 2003. 
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2.15.9   Optimizing the inventory of hazardous chemicals 
The information shall be submitted to SPCB regularly along with rational-action plan to be 
submitted to SPCB by May 31, 2003. 
 
 
 
                            Fig 9:Water generation and water consumption pattern  
 
 
2.16   AWARENESS OF THE FACTORY REGARDING CONSERVATION OF 
WATER 
 
• The industries which have a best environment management practices having ISO certified 
i.e. ISO 9000, ISO 14000, approved by a drug control authority like USFDA and other 
certified Environment Management System (EMS) consume water with less variation in 
compare to other industries. The water use pattern of such manufacturers is totally controlled, 
because no variation in material and water input can be allowed without prior approval of 
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USFDA. In those cases the water consumption for that industry is considered in arriving at 
guidelines for optimum water consumption. 
 
 
 
                            Table 7:CPCB’s guidelines for water comsumption 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter 3 
CASE STUDY OF LESANTO 
LABORATORIES 
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3.  LESANTO  LABORATORIES: 
 
 
 
Lesanto Manufacturing unit based at Palghar, Dist. Thane, spanning an area of more than 
26000 sq. ft. is well connected with good roads and has excellent transportation means to sea 
port, airport and major cities across India. 
-GMP requirements. Lesanto Laboratories 
has been awarded with the Certificate of Good Manufacturing Practice (GMP) as laid by the 
World Health Organization (WHO) and compliance to Schedule 'M', in respect of 
Manufacturing and Testing of Pharmaceutical Formulations & therefore approved as a WHO-
GMP compliant unit. 
3.1 Manufacturing Overview:- 
W H O GMP certified Tablets, Capsules, Liquid Orals, Non-sterile Ointments department 
with huge production capacity. 
material. 
In-house testing facilities (Quality Control/ Quality Assurance dept) and Product 
Development Cell to carry out R&D for new/ potential products. 
3.2 Infrastructure:- 
-of-the-Art self sufficient, independent and autonomous Quality Control Department, 
fully equipped with latest analytical instruments & Machinery guided by independent Quality 
Assurance Department. 
-
house Microbiology Department to carry out tests. 
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of fittings in coating system, Manufacturing etc. 
environmentally safe and help to enhance human life. 
3.3 Annual production capacity:- 
Sr no Department Capacity/ 
annum 
Capacity/annum * 
(10’s strips/bottles/tubes) 
1 Tablets 360mm 36mm 
2 Capsules 90mm 9mn 
3 Liquid Orals(100ml) 7,50,000Ltrs 7.5mn bottles 
4 Non-sterile Oinments(20g) 80,000Kgs 4 mn tubes 
                                Table no. 8 : Annual production capacity. 
 
3.4The procedure for operation and maintenance of effluent treatment plan at lesanto 
Procedure : 
Effluent management(operation): 
1. All effluent from plant is collected in common collection tank. 
2. The effluent from common collection tank shall go under gravity flow to 
equilisationtanks.here the PH of effluent shall be checked, as per the PH of effluent 
the required acidic or alkaline treatment shall be given in equilisationtank,for thorough 
mixing air sparging is done.the PH should be in between range 6-8 in equilisation 
tank. 
3. The eefluent from equilisation tank shall go through effluent transfer pumps to the 
primary clarifier where polymer dosing is carried out.the sludge from this tank shall 
go to the sludge drying bed by gravity flow. 
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4. The effluent from primary clarifier shall go to the aeration tank for aerobic  oxidation.i 
the aeration tank aerobic oxidation by air sparging.in aeration tank part of the sludge is 
recirculated from the secondary clarifier. 
5. The effluent from aeration tank then goes to secondary clarifier by gravity flow.in 
secondary clarifier,the agitator runs at slow RPM in order to settle the sludge at the 
bottom of clarifier. 
3.4.1 The procedure for D.M. plant regeneration. 
Procedure: 
1. Cation bed: 30 liters of HCL→ 100 liters of R.O. water →inject to cation bed and flush 
with   →  R.O. water for 15 minutes. 
2. Anion bed:-10 kgNaoH→100 liters of R.O. water   →    inject to anion bed and flush 
with R.O. water for 15 minutes. 
 Connect both the cation and anion bed and flush with R.O. water for 20 minute.     
3. Mixed bed:-resin separation in mixed bed must be done with R.O. water pressure and 
be confirmed by viewing through window for visible separation. After resin separation 
take 2.5 kg of NaoH dilute up to 50 liter and inject in mixed bed through upper end 
and flush with R.O. water for 15 minutes.  
 
 
 
 
 
 
 
 
 
 
 
\ 
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Photo No. 1: Inlet tank 
 
 
Photo No 2 : Equalisation Tank 
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Photo No.3 : Detention Tank 
 
 
Photo No.4 : Sludge drying beds 
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Photo No. 5 : ETP 
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Photo No.6: Top view of ETP ( sludge collection ) 
 
Photo No.7 : Effluent sample collection 
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Photo No.8 : Demineralisation units 
   
 
Photo No.9 :  RO unit 
                                      
  
 
 
 
 
 
 
Chapter 4 
COMPARITIVE STUDY 
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4.1 ALKEM LABORATORIES: 
 
4.1.1 About company: 
Established in 1973 and headquartered in Mumbai, India, Alkem began operations as a health 
care marketing company. Alkem has since grown to become India’s seventh largest 
pharmaceutical company with sales revenues exceeding USD 500 million with a CAGR of 
16% over the last five years. 
Alkem laboratory Ltd. is the manufacturer of pharmaceutical products. The factory is situated at Plot No. C - 
6/1/2, M.LD.C.Taloja, Navi Mumbai.  
As per Water Act, each industry is required to treat its effluents as per the standards laid down by state 
Pollution Control Board, for Disposal of their wastewater.  
For water pollution control, Alkem have up gradated the full-fledged Effluent Treatment Plant (ETP) to treat 
the effluents in order to achieve the standards.  
They have appointed toULTRA - TECH, (Air &Water Pollution Consultant) Thane, for designing,  
installation and commissioning of full-fledged Effluent Treatment Plant.  
4.1.2 PURPOSE: 
- Mis. ULTRA TECH, Thane, have prepared this Operation &Maintenance manual for the Effluent Treatment 
Plant, which describes the operational steps required to operate the Effluent treatment plant in the most 
efficient manner. Purpose of this document is to provide all assistance required to operate the plant in most 
efficient manner.  
The operation steps along with treatment units &trouble shooting problems are described subsequently in  
following annexures.  
 
INDIVIDUAL STREAM COLLECTION AND TRANSFER 
All raw effluents sreams are individually collected and transfer to the ETP for further 
treatment. 
Sr no. Particulars Details 
1 source All process unit,canteen,domestic,R& D department etc. 
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2 Treatment given Collection and transfer 
3 Objective of treatment Effluents streams are far away from ETP.therefore 
individual collection and transfer to the ETP. 
4 Resource involved Canteen effluent collection sump with transfer pump and 
level switch domestic and all process unit stream collect 
ion sump with transfer pump and level switch. 
R&D center and bottle washing streams are coming to 
ETP by gravity. 
 
4.1.3 NORMAL OPERATION   
As such operation in this unit are only collection of all individual industrial effluents streams 
from plant and transferred to Effluent Plant. 
Effluents from canteen are routed to the Canteen effluent collection sump. Where provision of 
level switch to be provided. Then Canteen effluent will be diverted to oil and grease trap with 
the help of effluent are routed to individual collection sump. All individual sumps are 
connected to each other and two pups are provided with level switch to transfer of all above 
effluent to oil & Grease trap through. 
Effluent from R & D Centre and bottle washing effluent shall be diverted by gravity to oil & 
Grease trap through bar screen. 
CHECK LIST : 
 Ensure that raw effluent is being receive without any choke up. 
 Run one pump for one shift (say 8 hours )& then switch over to another pump for 
trouble free operation. 
 Ensure that gland packing of pump is all right. 
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4.1.4   SCREEN CHEMBER AND OIL & GREASE REMOVAL 
As such oil & grease is present in the effluents. However, provision is made for removal of il, 
if any 
Sr. No Particulars Details 
1. Source All Individual streams from all process plant , canteen 
and domestic 
2. Treatment given Foreign material trap and Oil removal. 
3. Objective of treatment  Removal of oil 
4. Resources involve Bar screen chamber with bar screen oil & Grease trap 
with necessary baffle. 
 
NORMAL OPERATIONS:  
As such operations in this unit are only removal of foreign material and oil from of combined 
industrial as well as sewage effluents from plant. 
Effluents from plant are routed to the Screen chamber followed by bar screen. Main objective 
of bar screen is removal of foreign material which is comes from gravity line. After bar screen 
effluent will be diver to the oil & grease trap. The oil and grease trap is provided with 
necessary baffles is to hold the raw effluent and to separate the oil from the effluent and 
accumulation of oil in the middle chamber of the trap.This oil is to be scrapped manually from 
upper layer of the effluent. 
After removal of oil effluents from oil trap are directed to the equalization cum neutralization 
tank by gravity for further treatment. 
CHECK LIST:  
 Ensure that bar screen is being cleaned on regularly basis. 
 Ensure that oil or scum is being removed from the oil trap on regular basis. 
 Ensure that raw effluent is being received without any choke up. 
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4.1.5  EQUALISATION / NEUTRALISATION 
Sr.No. Particulars Details 
1. Source Combined industrial sewage effluent from plant 
after bar screen chamber and oil & grease trap. 
2. Treatment given Equalization & neutralization , Effluent transfer 
3. Objective of treatment  Removal of hydraulic / organic load 
variations 
 Neutralization of effluents if required 
(effluent are mostly neutral ) 
 Transfer of neutralized effluents. 
4. Resources involved  Equalization cum neutralization tanks 
 Aeration grid for mixing 
 Air blower 
 Effluent transfer pumps. 
 
All effluent streams from process plant and sewage effluent shall be directed to the 
equalization cum neutralization tanks after oil removal trap. The main objective of this tank is 
to equalize the hydraulic variations & neutralize the effluents. Two numbers tanks are 
provided with aeration gird. But both tanks are interconnected to each other and the operaion 
of the tanks will be single because incoming effluents are mostl neutral in nature. Therefore 
Provision of acid/alkali solution dosing has not been made for neutralizing the effluent. 
The normal operation will be as follows ; 
 After removal of oil , all effluents are diverted to the equalization tank. 
 Allow the effluent to receive into the tank. 
 Once the tank is 1/4thfilled , open the air inlet valve of the tank in operation . Adjust 
the airflow as required. 
 Once the tank is almost filled ( up to free board 500mm from top ). Check the ph with 
the help of pH meter or pH paper ( in comin effluent are mostly neutral in nature ) 
 Start one transfer pump Flow rate to be adjusted initially. To control the flow rate , re-
ciculation line is provided. Total two pumps are provided ( 1working +  1 stand by ). 
However normal transfer flow rate of the transfer pump should not exceed 5.0m3/hr. 
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 Effluent is pumped to the flash mixer for flocculants dosing. 
 Equailisation cum neutralization tank are provided with aeration grid connected to the 
air blower.ensure that air is supplied continouusly,during neutralization and transfer. 
 Ensure that effluent feed rate is not more than 5.0 m3/hr. 
 Check the PH of the eeffluent with the help of one line pH meter or b using pH paper 
regularily. 
 Record the pH on respective plant operation log sheet.pH of the effluent shall be 
monitored/recorded hourly. 
 Run one pump for one shift & then switch over to another pump for trouble free 
operation. 
 Ensure that gland packing of pump is all right. 
 Check the current dawn motors periodically.record all current readings and it shall be 
checked against rated current. 
 Ensure that motor fan is running smoothly & motor guard is properly placed. 
 Pumps are self primingpumps.priming will be required initially during 
commissioning.ensure that the flapper is working properly. 
 Check  tighten the bolts of the agitator frequently. 
 Stop the pump/air bolwerimmediately,if any undue noise or wobbing is observed. 
 Refer manufacturers manual for maintainance of the pumps(attached). 
 Never pump the effluents at very high rate to the flash mixer.always adjust the feed 
rate at about 5.0m3/hr .this can be done. 
 Never close air line during receiving & transfer of the effluents at equilisationtanks.if 
the air is not supplied,then effluents may go into anaerobic(specific condition). 
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Photo No. 10: Equalization cum Inlet tank. 
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4.1.6  Flash mixer: 
Sr 
no. 
Particulars Details 
1 source  Combined neutral effluent from equilisation cum 
neutralization tank. 
2 Treatment given Agitation and flocculation  
3 Objective of treatment Proper mixing of flocculants with effluent. 
4 Resource involved  Flash mixer tank 
 High slow speed agitator 
 Alum dosing system 
 Poly dosing system 
 
The neutralized effluents is to be pumped further to flash mixer tank, to facilitate the process 
of coagulant flocculation. 
The equalized & neutralized effluent is pumped through effluent transfer pumps to flash 
mixer tank. Add of flocculants is done to aid the settling process. The exact dosage of alum & 
polyelectrolyte can optimized during commissioning trials. The flocculants is to added from 
flocculants dosing tanks. 
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Photo No. 11: Flash mixer tank 
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4.1.7  SOLID LIQUID SEPARATION: 
SR 
NO. 
PARICULARS DETAILS 
1 Source Combined neutral effluent after flash mixer and 
flocculation. 
2 Treatment given Solid liquid separation. 
3 Objective of treatment Removal of inorganic load from effluent. 
4 Resource involved  Lamella settler 
 Primary settling tank 
 Sludge drying beds 
 
Process mechanism: 
The process of primary sedimentation is to remove suspended solids from the system. The 
equalized& neutralized effluent is pumped through effluent transfer pumps to flash  mixer and 
then lamella setter and primary settling tank. 
The process of primary sedimentation takes places in the lamella settler and primary settling 
tank. The clear supematant effluent will further flow to the aeration tank for biodegradation. 
The sludge is allowed to settle at the bottom of the lamella settler and primary settling tank. 
The settled sludge is drained onto sludge drying beds for drying. The period sludge draining 
can be optimized during the commissioning period depending on the solid load to the unit. 
4.1.8  TRANSFER OF SLUDGE TO DRYING BEDS: 
Open the drain valve of the lamella settler and primary settling tank and the valve near the 
drying bed end to be used. The drainig of sludge is to be continued till clear effluent is seen 
on the drying bed end . Allow the sludge to dry. Filtrate is collected the filtrate chamber 
which is directed to the equalization tank by gravity.The sludge drainig frequency can be 
adjusted at the time of commissioning. However as a safety , it can be drained once in hour. 
Check list : 
 In case , effluents are not available for longer time , empty out the primary 
clariflocculator tank in order to avoid the septic condition in the settling tank. 
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 Ensure that sludge flow by gravity to the primary clariflocculator tank. Ensure that 
complete sludge is drained onto sludge drying beds. 
4.1.9  SECONDARY TREATMENT ( BIOLOGICAL DEGRADATION ) 
Sr.No Particulars Details 
1. Source Clear overflow from primary settling tank. 
2. Treatment given Biological degradation of soluble organics. 
3. Objective of treatment Removal of BOD in the effluent. 
4. Resources involved  Aeration tanks with surface aerator 
 Secondary clarifier tank 
 Sludge recycle pumps. 
 Sludge drying beds. 
Activated sludge treatment is incorporated in order to degrade the organic waste with 
the help of bacteria. 
 Aeration tanks with floating aerator 
 Secondary settling tank 
 Sludge recycles pumps 
 Sludge drying beds ( for de-watering ) 
The microbial culture developed in the Aeration tank is called Mixed liquor suspended solids 
( MLSS ), which is supposed to be maintained in the order of 2500-3000 mg/lit. The volatile 
part of MLSS called the MLVSS which is an indicator of the growth of bacteria. The oxygen 
required for the bacterial growth is supplied through surface aerator. 
The clear overflow from primary settling tank is fed to the Aeration tank. The microbial 
culture in the Aeration tank degrades the effluent. The partially degraded effluent along with 
the biomass overflows from the Aeration tank to the Secondary clarifier tank for settlement of 
the biomass. The settled biosludge is pumped back to the Aeration tank to maintain the 
required concentration of MLSS in the Aeration tank.  
The overflow from the Secondary settling tank flows to the treated effluent collection cum 
pressure sand fliter feed tank . The excess sludge is drained on to the sludge drying bed. 
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Nutrients requirement shall be checked from time to time . Nitrogen & phosphorus 
requirement is as follows; 
4.1.10 TERTIARY TREATMENT 
Sr . No Details Remark 
1. Source  Biologically treated effluent after secondary clarifier tank 
2. Treatment give Increase dissolved oxygen,chemicaloxidation,Filtration& 
polishing 
3. Objective of 
Treatment 
Oxidation , removal of trace suspended solids,odour,colour 
4. Units Involved  Treated effluent collection cum PSF feed tank 
 Filter feed pumps 
 Pressure sand filter 
 Final treated effluent holding tank 
 Final treated effluent disposal pump 
 
Clear overflow from Secondary clarifer tank will be taken to the treated effluent collection 
cum pressure sand filter. From Treated effluent collection cum PSF feed tank, effluent are 
pumped to the pressure sand filter to remove trace quantities of suspended of suspended 
solids. Same effluent can be used for backwish of pressure sand filter Backwash drain from 
filters is directed to the sludge drying bed. Outlet from pressure sand filter is collected in final 
treatment effluent sump for disposal to CETP. 
Filtration: 
The effluent will pass through pressure sand filter for removal of susupended solids in the 
effluent. 
Start up of Filter feed pumps: 
Open the valve of the suction line. Start the pump.In this case, one of the pumps will be used 
for this operation. Gradually open the delivery valve. 
Operation of pressure Sand filter 
These filters are basically consists of fabricated MS pressure vessel internally painted with 
anticorrosive paint. The filter consists of necessary nozzles , bottom collecting system and top 
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bell mouth or a header , one charge of filter media. Externally , the unit is provide with frontal 
pipe-work, set of valves , gaskets , pressure gauge, sample cocks, and air release pipe. 
NORMAL OPERATION: 
Before operation of the filter ensure that it has water above the sand bed level. Now open inlet 
valve, outlet valve & air release vavle. The water is flowing from top of bottom inside the 
vessel. The suspended particles remain of the top of the sand layer . The water flowing from 
below  is collected at the bottom and then comes out through the outlet valves filtering all 
suspended solids. 
 Open air release valves while starting the unit and close the valve when all air is released 
from vessel and water coming out from the same. As the dirt accumulates at top of sand layer, 
the pressure difference at inlet and outlet increases. When the pressure difference exceeds 
0.5kg/cm2, the unit requires back-washing. 
Sr No. Details  Remark 
1. Source  Primary settling tank bottom darin. Excess sludge from 
the secondary settling tank. 
2.  Treatment given Gravity sand filtration and de-watering through solar 
evaporation. 
3. Units involved   Sludge Recycle pumps 
 Sludge Drying Beds 
 
Purpose: 
The main objective of sludge drying beds is to de-water and dry off the  excess sludge from 
Primary and secondary tank. 
The process involves physical straining of sludge water mixture through layers of gravel and 
stone with definite interstices. 
The top most layer of sludge drying beds is coarse sand, followed by fine stone aggregates, 
which is followed by gravel. 
The filtrate coming out from the bottom of bed is directed to the equalization tanks by gravity. 
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The filtrate coming out from the bottom of the bed is directed to the equalization tanks by 
gravity. 
The dried cake from the top of the bed shall be disposed off suitably. 
 
4.1.11  Sludge drying beds(SDB) : 
Normal operation for Secondary sludge: 
 Open the drain valve of the secondary settling tank . Start the return sludge pumps. 
 Open the sludge drain line to SDB. Actual sludge drain period shall be adjusted at the 
time of commissioning. 
 Allow the akudge to flow into the SDB. 
 Ensure that the inlet valve of other beds properly shut down. 
 Allow the sludge to fall onto the sludge drying beds. 
 Close the valve after a uniform layer of about 300mm thick is built up. 
 Stop the sludge return pump after this operation in case of secondary clarifier tank. 
 Allow the sludge to dry off in open atmosphere for about 7-10 days till it becomes 
dewatered and dries off. 
 Manually scrap the dried sludge sludge and dispode it off. 
 Direct the filtrate from the bottom of the beds OMESTIC to equalization tanks. This 
filtrate is directed to the equalization tank by gravity. 
Transfer of primary sludge to drying beds: 
Open the drain valve of the primary settling tank and the valve near the drying bed end to be 
used. The draining of sludge is to be continued till clear effluent is seen on the drying bed 
end. Allow the sludge to dry. Filtrate is collected the filtrate chamber which is directed to the 
equalization tank by gravity. The sludge draining frequency can be adjusted at the time of 
commissioning. However, as a safety, it can be drained once in a hour. 
 
4.1.12   SOLUTION PREPARATION & DOSING 
Preparation and dosing of alum/polyelectrolyte Solution: 
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4.1.12.1  ALUM DOSING AT FLASH MIXER: 
One No. of alum dosing tank is provide with air grid to prepare & dose the alum solution. 
High speed Agitator is provided to mix the contents for flash mixer. 
One no. of dosing pumps is provided for dosing Alum solution of required dose. 
Capacity of the tanks is 5000lit. However, the effective working volume shall be less around 
4800 lits. 
Normally keep around 200mm free board. 
Prepare about 5-10% alum solution. 
The tank can be calibrated with respect to height. 
Dosing of the alum solution is by using dosing pump. 
While preparation & dosing of alum solution, ensure that air sparging to be on and safety 
precaution taken by opetor. 
4.1.12.2 POLY ELECTROLYTE DOSING AT FLASH MIXER: 
 One No. of poly dosing tank is provided to prepare & dose the Poly solution. Aeration 
grid is provided to mix the contents. 
 One Nos. of dosing pump is provided for dosing polyelectrolyte solution of required 
dose. 
 Capacity of the tanks is 5000lit. Howvever, the effective working volume shall be less 
around 4000lits. 
 Normally keep around 200mm free board. 
 Prepare about 0.1% poly solution -1kg 
 The tank can be calibrated with respect to height. 
 Dosing of the poly.Solution is by using dosing pump. 
 While Preparation of poly solution, ensure that air sparging is on and safety 
precautions taken by operator. 
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Photo No.12 : Sludge tank 
 
 
Photo No.13 : Radiator tank 
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Photo No.14:ETP Layout of  Alkem 
 
Photo No. 15: Impact of  pharmaceutical waste on garden 
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4.2 Navjeevan Synthetics: 
Navjeevan Synthetics Private Limited 
(Navjeevan Synthetics specialises in manufacturing of fabric) 
 
4.2.1 Products 
Navjeevan Synthetics Private Limited (Navjeevan Synthetics) manufactures fabric under the 
brand name Paris Queen and Seven Star. It deals in cotton, manmade, polyester and viscose. 
 
4.2.2 Operations 
Navjeevan Synthetics was established in 1977. It is involved in weaving, dyeing and printing 
activities. The company operates through two plants located at Dombivali in Maharashtra 
with an installed capacity of 2,50,000 per month. The plant operates at 100% capacity 
utilisation working in two shifts. The domestic market accounts for 100% of the company’s 
total revenue. Some of domestic clients include Nobel House etc. The company showed a 
10% revenue growth in the last two years and expects its revenue to grow by 20% in the next 
two years.   
 
4.2.3   Turnover Bracket Rs 250-500 mn 
       Manpower 45 
       Director 
       D Somani 
 
4.2.4  Company Contact Details 
D-35-42-43, MIDC Phase II, Opp Anand Chem, Manapada Road Dombivili (East) 
Domivali-421203 Maharashtra. 
Phone : 91-0251-2870738 / 2870739 
Fax : 91-0251-2871604 
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4.2.5   Description : 
            Navjeevan Synthetics Pvt Ltd. It is a type of textile industry situated at 
Manpada road, MIDC, Dombivli (E). Its turnover per month is 250mn . Clothing has been the 
main production in it, hence emissions coming out are of chemical type. While manufacturing 
cotton, wool, nylon etc. the effluent emitting out has the presence of various chemical/colour 
impurities present in it. Total 3 batches of treatment are performed in a day.Batch timings are 
8-10, 1-3, 6-8. For each batch it takes around 1-1.5 hrs to complete the process. 
 
4.2.6   Objective:  
          To give primary, secondary treatment to waste water generated by navjeevan 
synthetics. 
 
4.2.7  Treatment units: 
 Equalization tank, clarifier tank, Rapid sand filter, Activated carbon filter, tube settlers, 
Supernet tank.  
 
Process Adopted: 
* The pH value of influent lies between 9-10.5  
1. The  water emitting out from various production units comes in equalisation tank 
(capacity- 40000 lit) where optimum dosage of coagulants having proportions 
lime- 25 kg  
poly- 60 gm/batch 
ferrous -35kg 
Hcl-70 lit/batch  
are been given per batch.  
2. Effluent is pumped out from equalisation tank to tube settlers where it is retained for 15-20 
min. The capacity of tube  settlers is 40000 lit. In this process, effluent is continously 
pumped until settlers are filled completely. 
3.After sometime, effluent is brought up to supernet tank by pipe system. The main purpose of 
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this to store further transfer  into pressure filters. 
4. Afterwards, from supernet tank it is carried out to pressure filters. 
 *Sand Filter-  
  Impurities are settled down with the help of sand and further transferred in connection with 
carbon filter. Here impurities cannot be removed completely. 
 *Activated carbon Filter- 
With the help of carbon filter, the water treated out a free from impurities and hazardous 
chemicals. 
5. The sludge is taken out at the bottom of the tube settlers tank when one cycle of batch 
completes its given time. One batch of sludge of consists of 10 bags and 1 bag consists of 
25kg sludge. 
6. Then effluent is brought up to supernet tank 2, where a sample of effluent are taken to test 
COD, BOD characteristics and found out to be  
COD - 250-300 mg/lit 
BOD - 300 mg/lit. 
7. Finally the waste water is pissed out to the outlet tank which is connected to the MIDC 
Tank, where bulk mass of waste water are gathered. 
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Photo 16 : Equalisation tank 
 
 
 
 
Photo 17 : Effluent pumped to clarifier 
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Photo 18: clarifier top view 
 
 
                      Photo 19 : Tube Settlers 
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Photo 20 : Supernet tank 
 
 
Photo 21: Activated sand & carbon filter.  
EIA of pharmaceutical waste a case study of Lesanto Laboratories 2015 
 
73 | P a g e  
 
 
 
Photo 22: Sludge drying machine  
 
 
 
 
Photo 23: pH meter 
  
 
 
 
 
 
Chapter 5 
MATERIALS AND METHODS  
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5. METHODS & MATERIALS  
 
 Methodology adopted at Lesanto laboratories 
 
5.1   Effluent Treatment Processes in Hetero Drugs 
Waste water treatment aims at the removal of unwanted components in waste waters in order 
to provide safe discharge into the environment. This can be achieved by using physical, 
chemical and biological means, either alone or in combination. A treatment plant is like an 
assembly in a factory where the various steps in purification are arranged in such a sequence 
that the quality of the output of one step is acceptable in the next step. Physical treatment 
methods such as screening, sedimentation, and skimming remove floating objects, grit, oil and 
grease. Chemical treatment methods such as precipitation, pH adjustment, coagulation, 
oxidation, and reduction,remove toxic materials and colloidal impurities. Finally, dissolved 
organics are removed by biological treatment methods. Tertiary treatment methods are used 
for further purification and for reuse of treated wastewater for various purposes. The 
treatment is done in particular stages, consists of Screening, Grit, oil & Grease chamber, 
Equalization cum Neutralization Tank, Flocculator, Aeration Tank. The effluent is 
characterized by evaluation of concentrations of TSS, PH, and conductivity before sending in 
to treatment process, important parameters to be considered for TDS are DO, MLSS, BOD, 
SVI (Sludge Volume Index). The waste water which is treated and stored in Effluent 
Treatment Tank may send to RO plant for further treatment , this water is used for gardening, 
cleaning purposes etc., else send to disposal in to water bodies. 
 
5.2  Monitoring of WWTP and its performance 
 
5.2.1  Evaluation 
Samples were collected from lesanto  pharma at different sampling points of ETP and 
characterize for parameters BOD, COD, pH, TSS, TDS, Alkalinity, Oil & grease etc. 
Overview of ETP and location of sampling points is given in Section below. 
 
5.2.2  Sampling procedures 
The reliability of the results of analysis of waste water samples depends up on the proper 
collection of a true representative sample from a large volume of waste water. The sample 
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after collection was transported,tested to the college environment lab and Company laboratory 
in a preserved condition. So that it will represent fairly and accurately conditions when the 
sample was collected. 
 
5.2.3   Sampling Schedule and frequency 
Grab samples were collected daily at lesanto pharma for a period of one week. Six sets of 
samples comprising of 
 Raw effluent [P-1] 
 Oil and grease trap [P-2] 
 Equalization tank [P-3] 
 Aeration tank 1 [P-4] 
 Aeration tank 2 [P-5] 
 Secondary Clarifier [P-6]  
Were collected and analyzed for the parameters given below. Samples for BOD, COD, 
Chlorides and Solids etc were analyzed in accordance with the procedure laid down in 
Standard Methods for the Examination of Water and Wastewater (APHA 1996) 
 
5.2.4  Instruments used for measurement of different parameters 
 
 
SR. 
No. 
 
 
PARAMETERS 
 
 
MEASUREMENTS 
1. pH pH meter 
2. BOD 
(Bio-Chemical oxygen Demand) 
BOD Analyzer 
3. TCOD 
(Total Chemical Oxygen Demand) 
COD Analyzer 
4. Chlorides Titrimetric Method 
5. Total Solids 
Total Dissolved Solids 
Total Suspended Solids 
Drying Oven 
Drying Oven 
Drying Oven 
6. Alkalinity Titrimetric Method 
7. Acidity Titrimetric Method 
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8. Oil & grease Separating funnel ,Evaporating dish & 
Oven                    
 
5.2.5Chemical oxygen demand(C.O.D) 
The chemical oxygen demand provides a measure of the oxygen equipment to that portion of 
the organic matter in a sample that is susceptible to oxidation by a strong chemical oxidant. 
Principle: 
Most type of organic matter are destroyed by boiling with a mixture of dichromate and 
sulphuric acid. A sample is refluxed with known amount of potassium dichromate and 
sulphuric acid and the excess dichromate is titrated with ferrous ammonium sulphate. The 
amount of oxidisable organic matter , measured as oxygen equivalent to the dichromate 
consumed. 
Apparatus: 
Reflux apparatus consisting of 250 ml Erlenmeyer flasks, with ground flask neck ,condenser 
and a hot plate or heating mantle to insure adequate boiling of the contents in the refluxing 
flask. 
Reagents: 
 standard potassium dichromate solution(0.25N): 
 Dissolve 12.259 g of K2Cr2O7 primary standard grade previously dried at 103 C for 2 
hrs in distilled 1000 ml of water.Note: 120 mg of sulphamic acid per litre of 
dichromate willeliminate the interference due to nitrates. 
 Sulphuric acid raeagents: 
 Concentrated H2SO4 containing 22 gms Ag2SO4 bottle   9.84 of Ag2SO4/lit 
conc.H2SO4. 
 standard ferrous ammonium sulphate titrant 0.1 N:26.2 
Dissolve 39 g of Fe(NH4) (SO4)2 6H20 analytical grade in distilled water.add 20 ml of conc. 
H2SO4 cool and dilute to 1000 ml. This solution must be standardized against 0.25 N 
potassium dicrromate solution daily. 
 Ferroin Indicator: 
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          Dissolve 1.785 g of 1, 10 phenanthroline dehydrate or 1.485 g monohydrate                        
together with 695 mg of FeSO4  7H2O in 100 ml distilled water. 
 Mercuric Sulphate 
 SILVER SULFATE : 
         If it is already dissolved in H2SO4 no need to add again. 
 PROCEDURE 
1. Place 0.4 gms of HgSO4 in refluxing flask. Dissolve it in 5ml H2SO4 regent .add 20 
ml of H2SO4 reagent keeping the refluxing flask in ice water bath. Add some glass 
beads and connect the flask to the condenser . Mix the reflux mixture , thoroughly 
before heating is started. 
2. Reflux the mixture for 2 hours. Cool and then wash down the condenser with 
distilled water. 
3. Dilute the mixture to about 150 ml with distilled water, cool to room temperature, 
add 3-4 drops of ferroin indicator and titrate against standard ferrous Ammonium 
Sulfate. Take as the end point the sharp colour change from blue green to reddish 
brown. 
4. Reflux in the same manner a blank consisting of 20 ml distilled water together with 
reagents.  
CALCULATION: 
mg/l COD = (a-b) x N x 8000 / ml sample taken 
a = ml of fe (NH4)2 (SO4)2 used for blank 
b= ml of Fe (NH4)2 (SO4)2 for sample  
N= Normality of FAS. 
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5.2.6  Determination of dissolved oxygen (D.O.) 
procedure steps: 
 Principle: 
The sample is treated with manganese sulphate,sodium hydroxide and sodium iodide and 
finally sulfuric acid. The initial precipitate og manganese hydroxide,Mn(OH)3 , which 
combines with dissolved oxygen in sample to form a brown precipitate of manganese oxide, 
forms manganese sulphate which acts as oxidizing agent to release iodine from Nal. The 
iodine which is stoichoimetrically equivalent to the dissolved oxygen is then treated with 
standard sodium thoisulphate. 
 Reagents: 
 mangnesesulphate solution: dissolve 480g of (MnSO44H2O)or 364 g of 
(MnSO4,H4O) in one litre distilled water. 
 alkali-iodide-azide reagent: dissolve 500 g of NaOH and 10 g of sodium azide (NaN3) 
& 135 g of Nal in distilled water and dilute to one liter (alternatively use 900 g of 
KOH and 150g of Kl). 
 sulphuric acid , conc.: 
 (1%) Stacrchindicator:dissolve 14 g of starch soluble powder in 100 ml of distiiled 
water .digest the solution by heating till the solution gets clear. Store the solution with 
1.25 g of salicylic acid per liter or by few drops of toluene. 
 stock sodium Thiosulphate(0.1N): dissolve 24.82 g of sodium thiosulphate in one liter 
distilled water,store the solution eith 5 ml CHCl3 or by 1.0 g of NaOH. 
 standard sodium thiosulphate(0.025N): take 250 ml of stock solution and dilute to one 
liter disiled water or by dissolving 6.025 g of sodium thiosulphate in one liter of 
distilled water. 
 Standardization of sodium thiosulphate (0.1N) 
 Procedure 
Collect the sample in 300 ml bottle, taking the care to avoid contact of sample with air. the 
bottle should be completely filled up by sample water. Add 2 ml of manganese sulphate 
solution followed by 2 ml of alkali iodide azide solution, dipping the end of pipette below the 
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surface. stopper and mixed thoroughly by inverting bottles 4-5 times. allow the precipitate to 
settle. 
 Carefully remove the stopper , immediately add 2 ml of conc. H2SO4 and restopper and 
dissolve precipitate by shaking the bottle. The amount needed for titration should correspond 
to 200 ml of original sample. Thus for total 4 ml of reagents 300 ml bottle is 
required.200*300 /(300-4)=203 ml.titrate with 0.025 N sodium thiosulphate solution using 
starch indicator.record the ml of titrant used. 
 Calculation: 
Since 1 ml of 0.025 N Na2S2O3=0.2 mg oxygen ,the ml of this solution used is equivalent to 
mg/lit of dissolved oxygen. 
D.O. mg/l=burette reading*8000*normality of Na2SO3/ml of sample taken (approx.. 200 ml) 
 Significance: 
 it is necessary to know DO levels to asses quality of raw water and to keep a check on 
stream pollution. 
 it is the basis of BOD test. 
 DO is necessary for all aerobic biological waste water treatment processes. 
 DO test is used to control amount of oxygen in boiler feed water as it is the important 
factor in corrosion. 
 
5.2.7   Determination of biochemical oxygen demand (B.O.D) 
Principle: 
the BOD is amount of oxygen required by bacteria for stabilization of decomposable matter 
under aerobic conditions. The quantity of oxygen required for the stabilization taken as a 
measure of decomposable organic matter. 
The sample of waste or an appropriate dilution is incubated for days at 27 C in the dark. the 
reduction in DO concentration during the incubation period yields a measure of BOD. 
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 reagents: 
 phospate buffer : Dissolve 8.5 g of KH2PO4,33.4 g of Na2HPO4,7H2O and 1.7 g of 
NH4Cli one liter of distilled water. The pH should be 7.2 without further adjustment. 
 magnesiumsulphate: Dissolve 22.5 g of MgSO4.7H2O in little distilled water and 
dilute to one litre. 
 ferric chloride solution: Dissolve 2.5 g of FeCl3 ,6H2O in distilled water and dilute to 
one litre. 
 calsium chloride solution:Dissolve 27.5 g of CaCl2 in little distilled water and dilute 
to one litre. 
 mangnesesulphate solution: Dissolve 480 g of (MnSO44H2O) or 400 g of 
(MnSO4,2H2O) or 364 g of (MnSO4H4O) in one litreditiled water. 
 Sulphuricacid , conc.: 
 (1%)Starchindicator:Dissolve 24.82 g of sodium thiosulphate in one litre distilled 
water. Digest this solution by heating till the solution gets clear.Store the solution with 
1.25 g of salicyclic acid per litre or by few drops of tolene. 
 Stock Sodium Thiosulphat (0.1N):Dissolve 24.82 g of sodium thiosulphate in one litre 
distilled water. Store the solution with 5 ml CHCl3 or by 1.0 g of NaOh. 
 Standard Sodium Thiosulphate(0.025N):take 250 ml of stock solution and dilute to 
one litre with distilled water or by dissolving 6.205 g of sodium thiosulphate in one 
litre of distilled water. 
 Standardization: pulverize 2 g of (K2Cr2O7)dry 120 deg. C for 4 hrs. cool in 
dessicator.weigh 0.21+(or -)0.01 g and transfer to a 500 ml glasss stoppered conical 
flask+100 ml water, swirl to dissolve+3 gm of Kl+2 gm of sodium 
bicarbonate(NaHCO3)+5 ml of conc. HCl……. Let stand for 10 min. in dark and 
titrate with sodium thiosulphate.solution until the solution has only a faint yellow 
colour + 2 ml of stach solution and continue the titration to the disappearance of blue 
colour. 
Calculation:  
Calculate the normality of sodium thiosulphate as follows: 
A=B/(0.04904*C)     where A=normality of thiosulphate 
     B=Grams of K2Cr2O7 
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     C=ml of thiosulphate required for titration 
 Apparatus: 
 Incubation bottles, 
 Incubator 
 other glass wear 
 Procedure: 
 Preparation of dilution water : 
 aerated required volume of disiled water in container bubbling compressed air for 1-2 
days to attain DO saturation. 
 Add 1 ml each phosphate buffer,magnesiumsulphate,calcium chloride, and ferric 
chloride solution for each litre of dilution water .mix well. 
 In case of waste which are not expected to have sufficient bacterial population add 
seed to the dilution water. Generally, 2 ml settled sewage is considered sufficient for 
1000 ml of dilution water. 
 Dilution of sample: 
 Neutralize the sample to pH around 7.0, if it is highly alkaline or acidic. 
 The sample should be free from residual chlorine . if it contain residual chloride 
remove it by using Na2SO3 solution as follows: 
Take 50 ml of sample and acidify with addition of 10ml 1+1 acetic acid. Add about 1 
g Kl titrate with Na2CO3 0.025 Nusing starch indicator.calculate the volume of 
Na2CO3 required per ml of the sample and add accordingly to the sample to be tested 
for BOD. 
 Sample having high DO content i.e. DO 9.0 mg/ldue to either aigal growth or some 
other person, reduce DO content by aerating or agitating the sample. 
 Make several dilutions of samples so as to obtain about 50% depletion of DO in 
dilution water but not less than 2 mgand residual oxygen after 3 days of incubation 
should not be less than 1 mg/l.prepare dilution as follows: 
 
 0.1-10.% for strong trade waste, 
 1-5% for raw and settled sewage, 
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 5-25%for oxidized treated effluent, 
 25-100% for polluted river waters.     
 Siphon the dilution prepared as in 4 in three labeled bottles as demonstrated and 
stopper immediately. 
 Keep one bottlr for determination of initial DO and incubate 2 bottles at 237 deg. C for 
3 days. See the bottle have water seal. 
 Prepare ablank duplicate by siphoning plain dilution water (without seed) to measure 
the O2 consumption in dilution water. 
 Fix the bottle kept for immediate DO determination and blank by adding 2 ml MNSO4 
followed by 2 ml alkali azide as described in the estimation of DO. 
 Determine DO in the sample and in the blank on initial day and after 3 days. 
CALCULATION : 
BOD mg/l = (B1-B2) – (D1-D2) x Dilution factor , where  
B1 = DO of diluted sample before incubation (1stday ) 
B2 = DO of diluted sample after incubated (3rdday ) 
D1 = Do of blank before incubation (1stday ) 
D2 = DO of blank after incubation ( 3rd day ) 
FACTOR CALCUATION: 
Factor =  
𝑁.𝑂𝑓𝑡ℎ𝑖𝑜𝑠𝑢𝑙𝑝ℎ𝑎𝑡𝑒×8 ×1
𝑚𝑙𝑜𝑓𝑠𝑎𝑚𝑝𝑙𝑒
×
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑓𝑜𝐵𝑂𝐷(600𝑚𝑙)𝑓𝑜𝑟𝐼𝐷𝑂&𝐹𝐷𝑂)
𝑆𝑎𝑚𝑝𝑙𝑒𝑡𝑎𝑘𝑒𝑛𝑓𝑜𝑟𝐷𝑂𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠
 
 
 E.g 
Factor = 
0.1 ×8 ×1000
50
×
600
200
 
 Factor for 50 ml sample = 48 
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5.2.8 TOTAL SUSPENDED SOLIDS & MLSS 
REQUIREMENT :  
1. Whatman Filter paper No. 41 
2. Funnels 
3. Oven 
4. Weigh balance 
 PROCEDURE :- 
1. Initially weigh the filter paper after drying it for some time. 
2. Take 50 ml of the effluent sample whose suspended solids are to be detemined in a 
measuring cylinder. 
3. Filter the effluent sample through the whatman filter paper. Allow the water to drain 
through the filter paper. 
4. Once the sample is filtered , dry the filter paper in oven at around 105-108 oc for 1 1/2 
hrs. (or till drying ). 
5. After drying, cool the filter paper in dessicator and take the final weight.   
CALCULATIONS: 
                    T.S.S. (mg/lit) = 
𝑓𝑖𝑛𝑎𝑙𝑊𝑡𝑖𝑛𝑔𝑚𝑠−𝐼𝑛𝑖𝑡𝑖𝑎𝑙𝑊𝑡𝑖𝑛𝑔𝑚𝑠 )𝑥 1000000
𝑚𝑙𝑜𝑓𝑠𝑎𝑚𝑝𝑙𝑒𝑡𝑎𝑘𝑒𝑛
 
 
5.2.9    DETERMINATION OF MIXED LIQUOR SUSPENDED SOLIDS(MLSS) AND 
MLVSS 
APPARATUS: 
1) Whatman Filter paper No.41 
2) Funnels 
3) Oven 
4) Weigh balance 
 
PROCEDURE: 
1) Initially weigh the dry crucible. 
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2) Once the sample is filtered, dry the filter paper in oven at around 105-1080 
C for 1 ½ hr (or till drying). 
3) After drying cool the filter paper in dessicator and take the final weight 
and keep in crucible for MLVSS. 
4) Crucible is to keep muffle furance at around 500-600 oC for ½ hr ( or till 
ignite ) 
5) After igniting , cool the crucible in dessicator and take the final weight.    
CALCULATION : 
 
M.L.S.S in mg/l = 
(𝑓𝑖𝑛𝑎𝑙𝑤𝑡.𝑖𝑛𝑔𝑚𝑠−𝑖𝑛𝑡𝑖𝑎𝑙𝑤𝑡.𝑖𝑛𝑔𝑚𝑠)×1000000
𝑚𝑙𝑜𝑓𝑠𝑎𝑚𝑝𝑙𝑒𝑡𝑎𝑘𝑒𝑛
 
M.L.V.S.S in mg/l = MLSS –VSS 
 
5.2.10   DETERMINATION OF OIL & GREASE 
PRINCIPLE 
This method of measurement is applicable to the determination of relatively non-volatile 
hydrocarbons, vegetable oils , animal fats, waxes , soaps,greases and related matter. 
APPARATUS : 
Seprating funnel   
 Evaporating dish  
 Oven                    
REAGENTS :   Hydrochloric acid ( 1:1 )                 Sodium sulfate 
             Petroleum ether 60oC – 80oC              Sodium chloride 
 PROCEDURE :  
 Take known quantity of sample. 
 Acidity with few drops of conc. HCL to pH 2 
 Shake well and transfer to the separating funnel. Add 25 ml of petroleum ether . If 
emuision is formed , add few Nacl crystals , as required to break the emulsion. 
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 Wash the upper layer by small quantity of distilled water. 
 Again shake well for two minutes. 
 Allow the layers to separate. 
 Drain the lower layer. 
 Collect the upper clear layer by filtering through a funnel containing solvent-
moistened filter paper and Na2SO4 in a pre-weighed evaporating dish. 
 Repeat solvent treatment to aqueous phases earlier separated. 
 Wash Wash the filter paper with an additional 10 to 20 ml petroleum ether. Pour the 
remaining extraction  also in the evaporating dish. 
 Dry it in oven at 70oC.After drying .take final weight.; Find out increase in weight in 
mg. 
 Run one blank by evaporating the same quantity of solvent used for extraction. 
 
CALCULATIONS : 
Oil and grease mg/l = 
𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐢𝐧𝐰𝐞𝐢𝐠𝐡𝐭𝐢𝐧𝐦𝐠×𝟏𝟎𝟎𝟎
𝐦𝐥𝐨𝐟𝐬𝐚𝐦𝐩𝐥𝐞
 
 
 
5.2.12   SLUDGE VOLUME INDEX 
Sludge volume index (SVI) is determined as the volume ( in ml ) occupied by 1 gm of sludge 
in a 1000 ml graduated cylinder after settling it for a period of 30 minutes. 
ANALYTICAL PROCEDURE:- 
1.  Take a 1000 ml graduated cylinder. 
2. Pour aeration tank sample into the cylinder and fill it up to the mark. 
3. Note the time and observe the settlement in ml after 30 minutes. 
CALCULATION 
              SVI =  
𝑆𝑒𝑡𝑡𝑙𝑒𝑚𝑒𝑛𝑡(𝑖𝑛𝑚𝑙)×100
𝑀.𝐿.𝑆.𝑆
 
 
  
 
 
 
 
 
 
Chapter 6 
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6.RESULTS AND DISCUSSION 
 
Samples were collected from six points. Sampling points are Raw effluent [P-1], Oil & grease 
Trap [P-2], Equalization tank [P-3], Aeration Tank 1 [P-4], Aeration Tank 2 [P-5] & 
Secondary Clarifier [P-6] to evaluate the performance of ETP. 
 
6.1   Effluent characteristics 
 
The physio-chemical characterization of effluent from equalization tank is given in Table  
below. The key pollutants in the wastewater from lesanto laboratories based drug industry are 
organic compounds and suspended solids and biogeneous elements. Biodegradability may be 
estimated on the basis of ratio between BOD5 & COD. BOD5: COD ratio obtained from the 
literature data. In the present case BOD5: COD [691/1300] was found to be 0.53, which 
indicate that most of the organic compounds in the wastewater from lesanto pharma  are 
easily biodegradable. Suspended solids in wastewater from ETP was found to be 687 mg/L. 
Suspended solids in wastewater from lesanto pharmaceutical originates from coagulated 
effluent of chemicals from drug processing units. 
 
Table No. 9 : Characterization of effluent from Equalization Tank of Drug based 
Industry 
S.No. 
 
Parameters 
 
Concentration 
1 pH 
 
6.8 
2 BOD5 at 20º C [mg/L] 
 
620 
3 TCOD [mg O2/L] 
 
1290 
4 TS [mg of TS/L] 
 
1956 
5 TSS [mg of TSS/L] 686.7 
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6 TDS [mg of TDS/L] 
 
1237 
7 Chloride [mg Cl-/L] 
 
108 
8 Alkalinity [mg CaCO3/L] 
 
460 
9 Oil & grease [mg/L] 
 
16 
 
 
6.2   Standards for Waste Water Quality 
S.No. Parameters Collection 
site 
Frequency Standards 
Inlet 
Standards 
Outlet 
1 pH Inlet & outlet Daily 9.5-11.0 6.5-8.5 
2 BOD mg/l Inlet & outlet Daily 1500-2000 100 max 
3 COD mg/l Inlet & outlet Daily 4000-5000 250 max 
4 TDS mg/l Inlet & outlet Daily 2000-3000 2100 max 
5  TSS mg/l Inlet & outlet Daily 1000-1500 100 max 
6 Suspended solids Inlet & outlet Daily 600 100 max 
7 Chlorides Inlet & outlet Daily 250 1000 max 
8 Alkalinity Inlet & outlet Daily 200 600 max 
9 Oil & Grease Inlet & outlet Daily 60-80ppm 10 max 
# These standards shall be applicable for industries, operations or processes other than those 
industries. Operations or process for which standards have been specified in Schedule of the 
Environment Protection Rules 1989. 
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6.3   ETP  
Wastewater from lesanto laboratories was treated by simple conventional method. Sequence 
of operations is explained in methodology. The performance of ETP is evaluated by 
parameters pH, TSS, TDS, COD, BOD, Oil & grease etc. The data is given below in Tabular 
form. 
 
6.4  pH 
 
The use of acid, alkali, cleansers in lesanto pharma typically results in highly variable 
wastewater pH values. Literature data indicated that pH value ranged between 6.2-8.2 with an 
average of 6.56 (P-1) - 8.04 (P-6). The pH value is increased from acidic to base.  
 
Table No. 10: pH 
Samplin
g 
Points 
20 
sept 
 
21 
sept 
 
22 
sept  
23 
sept  
24 
sept  
25 
sept  
27 
sept  
28 
sept  
Mean S.D 
P-1 6.8 6.2 6.9 6.5 6.5 6.7 6.6 6.3 6.56 0.24 
P-2 6.9 6.5 7 6.7 7.1 6.8 7.1 6.3 6.80 0.29 
P-3 7.1 7.3 7.2 7.1 7.5 6.8 7.5 7.1 7.20 0.23 
P-4 7.8 7.9 8.1 7.5 7.8 7.5 7.9 7.8 7.79 0.20 
P-5 7.8 7.9 8.2 7.8 8 7.7 7.9 7.8 7.89 0.16 
P-6 7.9 8 8.2 8 8.1 8.2 8 7.9 8.04 0.12 
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6.5   BOD 
 
Data presented in Table  shows variation of BOD5 at different sampling points. BOD5 in raw 
effluent was found to be average 690.25 and after final treatment in secondary clarifier it is 
found that the BOD value is 34.25 (mg/L) gives consolidated information in the 
characteristics of six sampling locations of ETP. 
 
Table No. 11: BOD5 at 20 0 C (mg/L) 
Sampli
ng 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
Mean S.D 
P-1 704 698 617 681 694 693 727 708 691 32.49 
P-2 615 647 598 635 678 587 591 637 624 31.51 
P-3 605 605 560 590 598 565 580 621.6 591 21.16 
P-4 340 210 212 230 205 200 190 200 224 48.55 
P-5 210 199 185 174 198 168 170 170 184 16.24 
P-6 25 32 48 28 27.5 41 29 43.5 34 8.64 
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6.6.  TCOD 
 
Data presented in Table shows the monthly variation of TCOD at different sampling 
points.TCOD in the raw effluent was found to be 1304.38 mg/L (average), which is reduced 
to 43.49 mg/L (average value) after secondary clarifier. 
Table No.12: TCOD (mg/L) 
Samp
ling 
Point
s 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
Mean 
 
S.D 
P-1 1277 1310 1297 1318 1305 1278 1317 1333 1304 19.62 
P-2 1246 1287 1260 1244 1270 1267 1274 1269 1265 14.32 
P-3 1220 1188 1190 1211 1145 1045 1202 1223 1178 59.13 
P-4 613 642 525 530 610 690 649 650 614 58.64 
P-5 490 654 518 517 534 528 546 518 538 49.54 
P-6 41 44.7 40 41.7 47 51 43 39.5 44 3.93 
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6.7   Total solids 
Data presented in Table  shows the weekly variation of Total solids at different sampling 
points.Total solids in the raw effluent was found to be 3647 mg/L (average P-1), which is 
reduced to 1125 mg/L (average value) after secondary clarifier. 
 
Table No. 13: Total solids (mg/L) 
Sampli
ng 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24sep
ept 
 
25 
sept 
 
27 
sept 
28 
sept 
 
Mean S.D 
P-1 3740 3510 3746 3640 3548 3576 3752 3670 3648 95.36 
P-2 3280 3440 3600 3450 3466 3310 3666 3650 3483 146.11 
P-3 1980 1980 1960 2180 1990 2079 2060 2037 2033 72.96 
P-4 1880 1700 1850 2120 1990 1950 1960 1950 1925 121.30 
P-5 1780 1675 1856 1870 1795 1798 1850 1870 1812 65.88 
P-6 1080 1240 1120 1056 990 1276 1100 1140 1125 94.05 
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6.8   TDS 
Data presented in Table shows the monthly variation of Total Dissolved solids at 
differentsampling points. Total solids in the raw effluent was found to be 1615 mg/L 
(average-P1), which is reduced to 974 mg/L(average value) after secondary clarifier. 
                                              Table No. 14: TDS (mg/L) 
Sampli
ng 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
Mean S.D 
P-1 1690 1590 1530 1690 1668 1656 1578 1519 1615 69.87 
P-2 1247 1150 1250 1310 1290 1199 1180 1266 1237 55.43 
P-3 1038 1060 1190 1120 1222 1126 1156 1232 1143 70.98 
P-4 1055 1023 1060 1070 1212 1105 1121 1150 1099 60.90 
P-5 990 1002 1020 1018 1188 1110 1188 1100 1076 82.30 
P-6 986 990 998 986 990 975 890 980 974 34.78 
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6.9   TSS 
Data presented in Table shows the variation in TSS. TSS (2249 mg/L) in raw effluent was 
reduced to 52.75 mg/L after entrapment in secondary clarifier. Gradual decrease in TSS was 
observed in all tanks. Recycling of sludge and oxidation of substrate are the primary factors 
contributing to TSS in aeration tank. In the present case, no primary treatment is provided, so 
whatever removal is there i.e. because of secondary clarifier. A certain fall of concentration of 
TSS at sampling points P-4 & P-5 was observed which is due to oxidation of substrate 
and production of biomass. 
                             Table No. 15: Total Suspended Solids (mg/L) 
Sampli
ng 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
Mean S.D 
P-1 2050 1966 2436 2180 2350 2280 2272 2460 2249 175.51 
P-2 2010 1940 2400 2012 2299 2100 2005 2420 2148 194.14 
P-3 735 675 645 700 705 670 683 710 691 27.90 
P-4 650 635 610 667 654 540 546 630 579 101.92 
P-5 210 240 310 280 298 286 243 246 264 34.37 
P-6 48 53 62 42 70 59 42 45 52 10.26 
 
 
 
 
\ 
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6.10  Chlorides 
Table represent the concentration of chlorides at different sampling points. The concentration 
of alkalinity in raw effluent was 141 mg/L (average P- 1), as the effluent treated with 
chemical treatment unit the concentration reduced to 112mg/L(P-4). At the end of the 
treatment unit concentration reduced to72mg/L. (P-6) 
 
Table No.16: Chlorides (mg/L) 
 
Sampling 
points 
20 
sept 
 
21 
sept 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
MEAN S.D 
P-1 156 164 128 145 135 129 139 132 141 13.11 
P-2 145 154 112 130 121 120 117 129 129 14.43 
P-3 137.6 137 159 128 118 132 110 120 130 15.12 
P-4 124 100 115 115 104 127 103 112 113 9.81 
P-5 111 99.5 120 113 98 103 99 98 105 8.39 
P-6 76 65.6 87 85 45.9 60 87 77 73 14.73 
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6.11  Alkalinity 
Table shown below represent the concentration of alkalinity at different sampling points. If 
alkalinity is not removed before discharge in to aeration tank, it can interfere with the 
biological life in the surface water and create unsightly films. The concentration of alkalinity 
in raw effluent was 438 mg/L, as the effluent treated with chemical treatment by adding the 
base unit the concentration reduced to 434 mg/L. At the end of the treatment unit 
concentration reduced to 411 mg/L. 
 
Table No. 17: Alkalinity (mg/L) 
Sampling 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
Mean S.D 
P-1 469 433 448 458 437 449 445 460 438 13.52 
P-2 457 428.9 439 428.5 432.9 445 440 456 437 9.07 
P-3 456 421 418 433.6 426.7 443 438 453.5 434 14.05 
P-4 408 398.9 416 373 399 437 435 452 414 27.37 
P-5 400 394 410 413 338 436 435 428 419 17.57 
P-6 393 390 412 411 331 399 411 411.5 411 11.40 
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6.12   Oil & Grease 
Table shown below represent the concentration of oil & grease at different sampling points. If 
grease is not removed before discharge of treated wastewater, it can interfere with the 
biological life in the surface water and create unsightly films. The concentration of oil & 
grease in raw effluent was 25 mg/L, as the effluent passes through oil & grease trapping unit 
the concentration reduced to 16 mg/L. At the end of the treatment unit concentration reduced 
to 9 mg/L. 
 
Table No.18: Oil & grease (mg/L) 
Sampling 
points 
20 
sept 
 
21 
sept 
 
22 
sept 
 
23 
sept 
 
24 
sept 
 
25 
sept 
 
27 
sept 
 
28 
sept 
 
MEAN S.D 
P-1 27 23 22.6 27 23.9 26.9 23 25 25 1.94 
P-2 15.6 17 16.8 13 18 18.5 17.5 14 16 1.91 
P-3 13.9 12.5 13.8 12.9 15 17 12 13 14 1.61 
P-4 12 11.7 11.7 11.9 9.8 12.5 11 12.6 12 0.90 
P-5 11 11.4 10.9 11 9.5 11.5 10.8 10 11 0.68 
P-6 7.9 10 9 8.5 9 10 9 9 9 0.70 
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7.CONCLUSION 
 
pH: 
 The pH of the different sample is found to be within permissible limit and no further 
treatment for adjustment of pH is needed. As the pH value of  waste water is within 
permissible limit, it can be disposed off into water bodies. 
 
BOD: 
 After P-1, BOD is considerable , After P-2 to P-6, avg BOD is found to be 34mg/lit 
and it is found within permissible limit at outlet. Hence no further treatment is needed 
. 
COD:  
 The COD at inlet and outlet of a waste water sample is found to be 43.49 mg/lit i.e. 
less than 100. Which is within permissible limit and no futher treatment is required. 
TDS: 
 The average weekly variation of TSS is very less at inlet as compared to permissible 
limit at outlet i.e according to Schedule of the Environment Protection Rules 1989. So 
no further treatment is needed. 
TSS: 
 The values of TSS at inlet to outlet from P-2 To P-6 is very greatly reduced from 
2148mg/L to 52mg/L which is very less than permissible limit hence some another 
treatments will not needed. 
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CHLORIDES: 
 The concentration of alkalinity in raw effluent was 141 mg/L (average P- 1), as the 
effluent treated with chemical treatment unit the concentration reduced to 112mg/L  
(P-4). At the end of the treatment unit concentration reduced to72mg/L. (P-6) Which 
indicates that it’s a allowable limit & further treatment is not required. 
 
ALKALINITY: 
 
 The concentration of alkalinity in raw effluent was 438 mg/L, as the effluent treated 
with chemical treatment by adding the base unit the concentration reduced to 434 
mg/L. At the end of the treatment unit concentration reduced to 411mg/L, indicating 
under limiting value for alkalinity which is less than 600mg/L as maximum limit. 
 
OIL & GREASE: 
 
 The concentration of oil & grease in raw effluent was 25 mg/L, as the effluent passes 
through oil & grease trapping unit the concentration reduced to 16 mg/L. At the end of 
the treatment unit concentration reduced to 9 mg/L, Hence at outlet some other 
treatment is mandatory but not compulsory because it is very near to maximum 
permissible limit which is 10mg/L. 
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8. SUGGESTION & FURTHER SCOPE 
 
 BOD observed is under permissible limit but when it undergoes through shock loading 
, BOD is likely to vary . Hence in that case to give protection, ASP can be provided 
between primary and secondary clarifier. 
 
 The Sludge which was collected from various units , the company was very much least 
bothered about the sludge disposal. They were just drying the sludge on open terrace 
in company itself and disposing off into the garden adjacent to company. Using 
modern technologies, various units can be implemented in working plant for sludge 
treatment & Some by product recovery can be possible. 
 
 
 The Lesanto Laboratories can think over the new technology named Zero waste 
generation for minimizing the waste. 
 
 The sludge can be disposed off  by incineration after further chemical analysis. 
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